

# Herpesviral–bacterial interactions in periodontal diseases

JØRGEN SLOTS

Periodontitis is one of the most complex infectious diseases of the human body. Individual periodontal lesions may harbor millions of genomic copies of herpesviruses (179) as well as papillomaviruses, human immunodeficiency virus (HIV), human T-lymphotropic virus type 1, torquetenovirus, and hepatitis B and C viruses (190). Herpesvirus-infected periodontal sites tend to exhibit more breakdown than herpesvirus-free sites, and a herpesviral active infection is associated with an elevated risk of progressive periodontal disease (189). Furthermore, the oral cavity supports more than 700 bacterial species, and the periodontal pocket area harbors more than 400 bacterial species (148). Periodontopathic bacteria, such as *Porphyromonas gingivalis* and *Tannerella forsythia*, possess virulence factors involved in colonizing periodontal sites, neutralizing local host defenses and destroying periodontal tissues (78, 192).

The host immune response attempts to control both pathogenic viruses and bacteria in periodontal sites. However, it is unclear if various immune mediators, such as certain cytokines and chemokines, exert primarily a protective or a destructive role in periodontal disease. Also, some immune mechanisms that are active against viruses may diminish antibacterial immune responses, and vice versa. It may be that periodontitis is the result of extensive and partly opposing immune responses against viral–bacterial combined infections (179). Major advances in the diagnosis, prevention and treatment of periodontitis probably depend upon a better understanding of the pathogenic infections and the associated host responses.

This review article presents evidence that viruses and bacteria in aggregate produce a greater pathogenic effect than the sum of the individual agents, and discusses how the concept of a herpesviral–

bacterial combined infection may change our understanding of the pathogenesis, and possibly the management, of destructive periodontal disease. Emphasis is placed on synergistic interactions between periodontal Epstein–Barr virus and cytomegalovirus, and major suspected periodontopathic bacteria.

## Viral–bacterial synergy in medical infections

Respiratory disease represents the best-known example of serious viral–bacterial co-infections (113, 129). Worldwide, respiratory infections give rise to more disease and death than any other human infection and are one of the leading causes of morbidity and mortality (121). Seasonal influenza in the USA is estimated to result in more than 200,000 hospitalizations and 36,000 deaths annually (218). The great ‘Spanish flu’ influenza pandemic of 1918–1919 caused 20–50 million deaths worldwide and an estimated 675,000 deaths in the USA, affecting mostly young adults and not the usual children and old individuals. At the peak, half of the world’s population was clinically infected. During the influenza pandemic years of 1918–1919 (type A influenza, subtype H1N1) and 1957–1958 (type A influenza, subtype H2N2), the incidence of secondary bacterial pneumonia, the most common cause of excess mortality during influenza outbreaks, varied between 2 and 18% in different populations (123). The swine-origin influenza A outbreak of 2009 involved a novel H1N1 strain. The main bacteria in influenza-associated pneumonia are *Streptococcus pneumoniae*, alpha-hemolytic streptococci, *Haemophilus influenzae*, *Staphylococcus aureus* and *Moraxella (Branhamella)*

*catarrhalis* (123). A combined infection with influenza viruses and *S. aureus* causes particularly severe and fatal pneumonia in both children and adults (29). Respiratory viruses other than the influenza viruses can also interact pathogenically with bacterial pathogens, for example human parainfluenza virus with *S. pneumoniae* (50) and adenovirus with *Bordetella pertussis* (185). A study of community-acquired childhood pneumonia revealed that mixed viral-bacterial infections, which comprised about 75% of the pneumonias studied, resulted in more severe inflammation and clinical illness than single viral or bacterial infections (87).

Viruses can induce alterations in the respiratory tract, which allow resident bacteria to multiply to levels capable of inducing inflammation (6). Respiratory tract viruses can inhibit the ciliary activity of the respiratory epithelium and thereby increase the risk for bacterial superinfection (6). Respiratory cells infected with influenza A virus, respiratory syncytial viruses or adenoviruses show enhanced bacterial adherence in both *in vitro* and *in vivo* model systems (69). The influenza virus may predispose to secondary bacterial pneumonia by denuding the respiratory epithelium and exposing basement membrane elements (e.g. fibrinogen) to which bacteria can attach (47, 123). An influenza virus infection can also cause prolonged desensitization of lung sentinel cells to toll-like receptor ligands, resulting in a reduced presence of neutrophils and an increased secondary bacterial load (39). In addition, alteration of neutrophil functions by the influenza virus may decrease the clearance of pulmonary bacteria (97, 104).

Acute otitis media has been linked to synergistic interactions between viruses and bacteria (7). Otitis media is often associated with viruses, such as rhinovirus, respiratory syncytial virus, adenovirus, coronavirus, influenza virus (232), cytomegalovirus (238) and other herpesviruses (20), as well as with bacteria, including *H. influenzae*, *S. pneumoniae*, *M. catarrhalis*, and *Prevotella* and *Peptostreptococcus* species (19). Acute otitis media with a tympanostomy tube showed *S. pneumoniae*, *S. aureus*, *H. influenzae*, *Pseudomonas aeruginosa* and yeast (166). Viruses were detected in 65% of acute otitis media samples that were positive for *H. influenzae*, in 77% of samples that were positive for *S. pneumoniae* and in 73% of samples that were positive for *M. catarrhalis* (170). Tympanic membrane changes with acute otitis media are more severe in patients co-infected with respiratory viruses and bacteria than in patients who have a single infection with either of the two types of infectious agents (237). Viruses interact with bacteria in acute otitis

media to boost the local inflammatory process and also have a profound adverse effect on resolution of the disease (75).

Other human diseases seem also to have a combined viral-bacterial etiopathogeny. Recurrent bacterial sinusitis may develop as a complication to viral colds (5). Infectious mononucleosis caused by infection with Epstein-Barr virus can give rise to tonsillar upgrowth of *Prevotella intermedia* and *Fusobacterium nucleatum*, and subsequently pharyngotonsillitis (18). The Lemierre's syndrome, which is characterized by severe pharyngitis and sepsis, can occur as a sequel to Epstein-Barr virus-induced mononucleosis and is frequently associated with an overgrowth of *Fusobacterium necrophorum* (53). Gastroenteritis is often associated with mixed infections of viruses (rotavirus, adenovirus, norovirus, astrovirus) and bacteria (pathogenic *Escherichia coli*, *Salmonella*, *Shigella*, *Campylobacter jejuni*), and the combined viral-bacterial infection can lead to enhanced pathosis (117). Appendicitis has been associated with measles virus, adenovirus and herpesviruses, as well as with *Bacteroides fragilis*, *E. coli*, *Yersinia*, *Salmonella* and *Shigella* (91). In *Helicobacter pylori*-associated gastritis, the activation of a latent Epstein-Barr virus infection by monochloramine from infiltrating neutrophils can aggravate the gastric disease (128). In organ transplant recipients, cytomegalovirus and human herpesviruses type 6 or type 7 can induce serious opportunistic infections with bacteria, fungi, protozoa and other viruses, probably as a result of immunomodulation by the herpesviruses (12, 137, 150). A renal transplant patient developed a subhepatic abscess as a result of infection with cytomegalovirus and *P. gingivalis* (103). Vascular diseases occur at a higher frequency as a result of a combined infection with herpes simplex virus and *Chlamydia pneumoniae* (165) or periodontopathic bacteria (224) than from a single infection with either of these agents. Rheumatic heart disease and autoimmune myocarditis may involve dual infection with coxsackievirus and group A streptococci, which have the potential to dysregulate immune mechanisms and trigger an autoimmune reaction (167). HIV infection causes a variety of severe bacterial, fungal and viral infections (46, 100, 174, 242). Moreover, *P. gingivalis* may up-regulate expression of the HIV-1 R5-specific co-receptor CCR5 in oral keratinocytes and thereby increase the risk for oral infection and dissemination of R5-tropic HIV-1 strains (58). Also, various gram-positive and gram-negative bacteria of the periodontitis biofilm have the capacity to re-activate HIV in latently infected T cells,

macrophages and dendritic cells (80), and the vaginosis bacteria *Prevotella bivia* and *Peptostreptococcus asaccharolyticus*, but no other vaginal bacteria studied, are potential activators of HIV expression in monocytoïd cells and T-lymphocytic cells (72).

Animal models have been used to study viral–bacterial interactions. Respiratory pathosis was enhanced in mice when the influenza virus or other viruses co-infected with bacteria (198). In a mouse model of pathogenetic synergy, an influenza virus infection antecedent to an *S. pneumoniae* challenge caused pneumonia and led to 100% mortality, whereas an infection with *S. pneumoniae* prior to an influenza virus infection provided protection from influenza and improved survival rates (123). Immune mediators, including cytokines and chemokines, through toll-like receptors/mitogen-activated protein kinase pathways, seem to play important roles in the pathogenesis of the influenza virus–*S. pneumoniae* co-infection (184). Calves dually infected with bovine respiratory syncytial virus and *Haemophilus somnus*, both bovine respiratory pathogens, contracted lung disease and harbored *H. somnus* in the lungs, whereas the lungs of mono-infected calves showed neither pathosis nor *H. somnus* infection (57). Acute otitis media was induced in 63% of mice that had been stably colonized by *S. pneumoniae* and then infected with the influenza virus, whereas all mock-infected mice remained free of disease (122). Mice infected with herpes simplex virus, adenovirus or vaccinia virus revealed enhanced susceptibility to *E. coli* pyelonephritis (59). Mice inoculated intraperitoneally with murine cytomegalovirus together with *P. aeruginosa*, *S. aureus* or *Candida albicans* exhibited mortality rates of 80–100%, whereas immunization against murine cytomegalovirus abrogated the synergistic effect on mortality for all combinations of the infectious agents studied (70). In immunocompromised rats, a symptomatic infection with rat cytomegalovirus induced severe neutropenia and subsequently a high rate of enteric gram-negative rod bacteremia (201). A markedly higher mortality rate was found in mice co-infected with murine cytomegalovirus and *P. gingivalis* than in mice mono-infected with either cytomegalovirus or *P. gingivalis* (203). A significantly lower level of systemic interferon-gamma was detected in the dually infected mice than in the mono-infected mice, suggesting that *P. gingivalis* was able to reduce the antiviral interferon-gamma response and thus increase the pathogenicity of the co-infecting cytomegalovirus (203).

For completeness, a latent herpesvirus infection may, in some experimental settings, up-regulate the activation state of the innate immunity, thereby providing immune benefits for the host. Mice latently infected with murine Epstein–Barr virus or cytomegalovirus can show resistance to infection with the bacterial pathogens *Listeria monocytogenes* and *Yersinia pestis* (10). However, the herpesvirus-induced protection against bacterial infection seems to be transient, lasting only a few months (236).

Collectively, numerous studies of natural diseases and experimental infections conclude that viral–bacterial co-infections produce more disease than single infections with either of the two types of infectious agents. Early studies on viral–bacterial synergism emphasized a decreased clearance or an enhanced pathogenicity of the bacteria involved in the infectious complex, but more recent investigations also point to the possibility of an increased virulence of the virus. As millions of herpesviruses and bacteria can inhabit individual periodontitis sites (179), it is reasonable to assume that herpesviral–bacterial interactions also play a role in the development of human periodontitis.

## Herpesviruses in periodontal diseases

### Diagnostic considerations

Studies from various countries have found genomic copies of Epstein–Barr virus and cytomegalovirus to be present in most periodontitis lesions and to be less prevalent in gingivitis and healthy periodontal sites (Table 1). Study-to-study variation in the detection of periodontal herpesviruses may be a result of (i) the clinical status of the study subjects, (ii) the viral diagnostic methods utilized, or (iii) true geographical/ethnic differences in herpesviral occurrence.

### Clinical status of the study subjects

Identification of periodontal herpesviruses is influenced by the sample site and method utilized. Because pathogen loads typically peak during periods of active disease, herpesvirus recovery from periodontal sites depends greatly on the accuracy of the clinical diagnosis. The difficulty of defining periodontitis for the purpose of research was recently pointed out (156). The use of patient age as a main criterion for distinguishing between ‘aggressive’ and ‘chronic’ periodontitis may not be a reliable indicator of active or stable disease. The term ‘normal’ periodontal site

**Table 1.** Recent studies on the prevalence of subgingival genome-copies of Epstein–Barr virus (EBV) and human cytomegalovirus (HCMV) in periodontal disease

Study (country)	Virus	Aggressive periodontitis; percentage positive samples	Chronic periodontitis; percentage positive samples	Gingivitis; percentage positive samples	Healthy/normal periodontium; percentage positive samples
Imbronito et al. 2008 (85) (Brazil)	EBV-1	33%	47%	20%	0%
	HCMV	48%	50%	40%	57%
Combs et al. 2008 (28),(USA)	HCMV	No data	4%	No data	0%
Chalabi et al. 2008 (22) (Iran)	EBV-1 + 2	No data	79%	No data	7
	HCMV	No data	59%	No data	0
Grande et al. 2008 (61) (Brazil)	EBV	No data	48%	No data	No data
	HCMV	No data	80%	No data	No data
Rotola et al. 2008 (168) (Italy)*	EBV	55%	46%	No data	8%
	HCMV	0%	0%	No data	8%
Ding et al. 2008 (40) (China)	HCMV	44%	No data	No data	13%
Botero et al. 2008 (16) (Columbia)	HCMV	No data	80%	No data	25%
Saygun et al. 2008 (179) (Turkey)	EBV	60%	No data	13%	No data
	HCMV	53%	No data	7%	No data
Sunde et al. 2008 (207) (Norway)**	EBV	No data	40%	No data	7%
	HCMV	No data	12%	No data	0%
Imbronito et al. 2008 (84) (Brazil)	EBV	No data	45%	No data	No data
	HCMV	No data	83%	No data	No data
Moghim et al. 2007 (133) (Iran)	EBV	No data	61%	No data	3%
Wu et al. 2007 (235) (China)	EBV1 + 2	No data	38%	20%	21%
	HCMV	No data	63%	49%	42%
Botero et al. 2007 (15) (Columbia)	HCMV	40%	60%	No data	18%
Watanabe et al. 2007 (230) (Brazil)	EBV	57%	No data	30%	No data
	HCMV	7%	No data	0%	No data
Wu et al. 2006 (234) (China)	EBV-1 + 2	No data	66%	32%	17%
Chen et al. 2006 (24) (China)	HCMV	No data	59%	No data	32%
Klemenc et al. 2005 (95) (Slovenia)	EBV	No data	44%	No data	0%
	HCMV	No data	3%	No data	0%
Konstantinidis et al. 2005 (96) (Greece)	EBV	No data	55%	No data	9%
Kubar et al. 2005 (98) (Turkey)	EBV	89%	46%	No data	No data
	HCMV	78%	27%	No data	No data
Li et al. 2004 (107) (China)	EBV	58%	23%	19%	No data
Tantivanich et al. 2004 (214) (Thailand)	HCMV	No data	34%	No data	3%
<b>Percentage average (percentage median) positive samples</b>	<b>EBV</b>	<b>65% (57%)</b>	<b>49% (46%)</b>	<b>22% (20%)</b>	<b>8% (7%)</b>
	<b>HCMV</b>	<b>44% (44%)</b>	<b>44% (55%)</b>	<b>24% (24%)</b>	<b>17% (11%)</b>

\*Gingival biopsies were studied. Patients received multiple sessions of nonsurgical periodontal therapy before virological sampling. Latent herpesvirus-7 was identified in 90% of the periodontitis lesions studied.

\*\*Patients received conventional periodontal therapy before virological sampling.

is sometimes used to suggest absence of attachment loss rather than inflammation-free gingiva. As herpesviruses may enter even slightly inflamed periodontal sites, sensitive polymerase chain reaction (PCR) techniques may show viruses in ‘unhealthy’ control sites. Conversely, periodontal therapy can markedly reduce herpesvirus subgingival counts and thus cause a significant underestimation of the viral load associated with untreated disease (177). Reliable data about the prevalence of periodontal herpesviruses may require study of virgin lesions with a well-defined disease-activity status.

Studies that examine a small number of periodontal sites in each subject will inevitably underestimate the prevalence of herpesviruses in the study population and the total number of herpesvirus genome-copies in the entire periodontium. Studies of herpesviruses in subgingival sites will also not account for the substantial herpesvirus counts residing within inflamed gingival tissue (98, 168).

### Viral diagnostic methods

The era of relying upon *in vitro* cell culture for routine laboratory diagnosis of viral infections has truly passed. Viral isolation indicates an active and possibly disease-producing infection, but isolation of viruses is difficult, costly and time-consuming. High-fidelity PCR-based techniques have become the standard for identification and quantification of periodontal herpesviruses (99, 146), and the transcription of late herpesvirus genes for structural proteins is understood to signify productive viral replication and is commonly used to indicate an active herpesvirus infection (60, 124). PCR identification of oral herpes simplex virus may yield two- to fourfold more positive samples than viral culture (42, 227). Nested PCR may unveil more periodontal sites that are positive for cytomegalovirus than viral culture or real-time PCR (16) or end-point detection PCR (23). Nested PCR technology is particularly efficient in detecting low viral loads (168). However, PCR primers that amplify templates of microbial communities at different efficiencies may yield biased results (86). Misamplification and false-positive herpesvirus results may emerge when there are shared regions of nucleotide sequences between herpesvirus species and unknown infectious agents. Nevertheless, as periodontal Epstein–Barr virus and cytomegalovirus have been identified using a variety of PCR primers in platforms of end-point detection PCR, nested PCR, reverse transcription PCR and real-time PCR, the risk of a systematic misidentification of these viruses is small. However, different PCR primers

and protocols may detect herpesviruses with a varying degree of proficiency (28), and technical expertise and quality assurance methods vary among laboratories (102, 144, 183). Preparation of the target nucleic acid constitutes a particularly vulnerable stage of PCR protocols.

### Geographical/ethnic differences in herpesviral occurrence

The genotype distribution and seroprevalence of Epstein–Barr virus (82, 175) and cytomegalovirus (147, 168) differ among populations. Similarly to medical infections (157), some herpesvirus subtypes may exhibit increased periodontopathogenicity. Glycoprotein B (gB) homologues within the herpesvirus family participate in virus entry and cell-to-cell spread, and the encoding gene is commonly used in genotyping (145). The cytomegalovirus gB-II genotype seems to predominate in chronic periodontitis, whereas the cytomegalovirus gB-I genotype is more closely related to gingivitis and a healthy periodontium (235). In addition, herpesviruses occur at a higher prevalence in low-income countries than in affluent countries (3), and the herpesvirus seroprevalence in high-income countries exhibits significant racial, educational and socioeconomic disparities, starting at an early age and persisting into middle age (43, 44, 243).

### Periodontal herpesviruses

Epstein–Barr virus and cytomegalovirus genomes have been identified in periodontitis lesions with prevalences ranging from a few per cent to more than 80% (Table 1). Cytomegalovirus seropositivity was identified in 95% of patients with periodontitis but in only 74% of patients with gingivitis ( $P = 0.057$ ) (88). Epstein–Barr virus (105) and cytomegalovirus (240) are also common inhabitants of peri-apical lesions of endodontic origin. Cytomegalovirus was detected in 32% of peri-apical abscesses exhibiting spontaneous pain (23).

To assess, in more detail, the linkage between herpesviruses and periodontitis, patients have been grouped according to disease severity. Table 1 reveals the presence of Epstein–Barr virus in 65% of aggressive periodontitis lesions and in 49% of chronic periodontitis lesions and of cytomegalovirus in 44% of aggressive periodontitis lesions and in 44% of chronic periodontitis lesions. Although the prevalence of Epstein–Barr virus and cytomegalovirus was similar in aggressive and chronic periodontitis, the herpesvirus infection may differ qualitatively in the



two diseases. An active ('productive') cytomegalovirus infection tends to be associated with periodontal sites showing no radiographic evidence of alveolar crestal lamina dura (211, 219), a finding consistent with disease-active periodontitis (158). An active cytomegalovirus infection has also been linked to increased gingival inflammation in immunosuppressed organ-transplant recipients (141). An acute herpes simplex virus-type 1 infection in a 26-year-old patient caused, within a few hours, extensive gingival recession (155). By contrast, a latent ('non-productive') herpesvirus infection is generally associated with chronic periodontitis sites exhibiting little propensity for disease progression (16).

Quantitatively, significantly more herpesvirus genomic copies inhabit progressive and untreated periodontitis lesions than stable or treated periodontitis sites (89, 90, 179). As many as  $8.3 \times 10^8$  Epstein-Barr virus DNA copies and  $4.6 \times 10^5$  cytomegalovirus DNA copies have been detected in samples of individual periodontal pockets (179), and even higher viral loads may reside within the gingival tissue of periodontitis lesions (98). Sunde et al. (208) identified up to one million genome-copies of Epstein-Barr virus in periodontal sites of a 63 year-old patient with refractory periodontitis. Herpesviruses other than Epstein-Barr virus and cytomegalovirus (110, 118, 138, 152, 168), as well as papillomavirus and other viruses (189), can also inhabit periodontitis lesions. Indeed, the total count of viruses approaches that of bacteria in some advanced periodontitis lesions. The abundance of herpesvirus genomic copies in individual periodontitis lesions translates into a heavy viral load for the entire periodontium of patients with severe and widespread periodontal disease. The high number of herpesviral copies in progressive periodontitis has implications for our understanding of the etiology of the disease.

### Herpesviral-bacterial periodontal associations

Table 2 summarizes statistical relationships between periodontal herpesviruses and bacteria. A study in China found that 17% of Epstein-Barr virus-positive periodontitis lesions, and 54% of cytomegalovirus-positive periodontitis lesions, contained as many as six to eight major species of periodontopathic bacteria (40). Periodontal Epstein-Barr virus and cytomegalovirus seem to be most closely associated with *P. gingivalis* and *T. forsythia* (179), two bacteria with high periodontopathic

potential (78). The link between cytomegalovirus and *P. gingivalis* appears to be particularly strong (193). Cytomegalovirus and *P. gingivalis* were linked to localized aggressive (juvenile) periodontitis in Jamaica with odds ratios of 4.6 and 7.8, respectively, but the cytomegalovirus-*P. gingivalis* dual infection was linked to the disease with an odds ratio as high as 51.4 (125). The significantly higher odds ratio of the cytomegalovirus-*P. gingivalis* co-infection than of the sum of the individual pathogens is suggestive of a pathogenetic synergy between the infectious agents. A study, in the USA, of 140 adults with gingivitis or periodontitis, linked Epstein-Barr virus-1 and cytomegalovirus to elevated occurrence of the pathogens *P. gingivalis*, *T. forsythia*, *P. intermedia*, *Prevotella nigrescens* and *Treponema denticola* (Table 3). In a study from Japan, *P. gingivalis* comprised 0.25% of total salivary bacterial counts in Epstein-Barr virus-positive periodontitis patients but only 0.02% (a 13-fold difference) in Epstein-Barr virus-negative patients (205). Periodontal Epstein-Barr virus (179, 207) and cytomegalovirus (85, 125, 140, 219) have also been related to the subgingival presence of the major periodontopathogen *Aggregatibacter actinomycetemcomitans*. An association between herpesviruses and anaerobic bacteria has also been demonstrated in periapical pathosis (171).

Herpes simplex virus may participate in periodontal disease in a subgroup of individuals (85, 89, 110, 138, 176, 178). Herpes simplex virus-1, in combination with *P. gingivalis*, *T. forsythia*, *P. intermedia* or *A. actinomycetemcomitans*, has been linked to periodontitis (85), and, in combination with *T. denticola*, *T. forsythia* or *Dialister pneumosintes*, to periodontitis and necrotic dental pulp (138).

Despite a large body of supporting evidence, well-designed studies of diverse populations are still needed to corroborate the findings of a relationship between various herpesviral-bacterial consortia and periodontal disease severity. Research is also needed to determine the extent to which herpesviral-bacterial co-infections in periodontitis represent pathogenetically significant interactions or merely an independent etiologic importance of each of the infectious agents.

### Immune responses to periodontal herpesviruses and bacteria

The periodontal immune response to herpesviral and bacterial infections is bifunctional with both tissue-

**Table 2.** Statistically significant associations between subgingival Epstein–Barr virus and human cytomegalovirus and periodontopathic bacteria

Herpesvirus	Bacterium	Study
Epstein–Barr virus	<i>Porphyromonas gingivalis</i>	Contreras et al. (31)
		Imbronito et al. (85)
		Saygun et al. (178)
		Saygun et al. (179)
		Sugano et al. (205)
		Sunde et al. (207)
	<i>Tannerella forsythia</i>	Contreras et al. (31)
		Saygun et al. (178)
	<i>Prevotella intermedia</i>	Saygun et al. (179)
		Contreras et al. (31)
	<i>Prevotella nigrescens</i>	Imbronito et al. (85)
		Contreras et al. (31)
	<i>Aggregatibacter actinomycetemcomitans</i>	Contreras et al. (31)
		Michalowicz et al. (125)
Cytomegalovirus	<i>Campylobacter rectus</i>	Sunde et al. (207)
		Saygun et al. (178)
	<i>Treponema denticola</i>	Contreras et al. (31)
		Botero et al. (15)
	<i>Porphyromonas gingivalis</i>	Contreras et al. (31)
		Michalowicz et al. (125)
Saygun et al. (178)		
Saygun et al. (179)		
Slots et al. (193)		
<i>Tannerella forsythia</i>		Botero et al. (15)
		Contreras et al. (31)
		Imbronito et al. (85)
<i>Prevotella intermedia</i>		Saygun et al. (178)
		Saygun et al. (179)
<i>Prevotella nigrescens</i>	Botero et al. (15)	
	Saygun et al. (178)	
<i>Aggregatibacter actinomycetemcomitans</i>	Contreras et al. (31)	
	Imbronito et al. (85)	
<i>Dialister pneumosintes</i>	Michalowicz et al. (125)	
	Nowzari et al. (140)	
	Ting et al. (219)	
	Slots et al. (196)	
<i>Campylobacter rectus</i>	Saygun et al. (179)	
	Contreras et al. (31)	
<i>Treponema denticola</i>	Contreras et al. (31)	

**Table 3.** Associations between Epstein–Barr virus-1 and human cytomegalovirus and periodontopathic bacteria\*

Virus	Bacteria or disease	Odds ratio	P-value
Epstein–Barr virus-1	Periodontitis severity	5.1	0.05
	<i>P. gingivalis</i>	3.4	0.01
	<i>P. gingivalis</i> + <i>P. intermedia</i>	4.4	0.005
	<i>P. gingivalis</i> + <i>T. denticola</i>	4.2	0.004
	<i>P. gingivalis</i> + <i>T. forsythia</i>	3.8	0.006
	<i>P. gingivalis</i> + <i>P. nigrescens</i>	2.7	0.05
	<i>P. gingivalis</i> + <i>T. forsythia</i> + <i>T. denticola</i>	4.1	0.005
	<i>P. gingivalis</i> + <i>P. nigrescens</i> + <i>T. denticola</i>	3.3	0.03
	Periodontitis severity	4.7	0.03
Cytomegalovirus	<i>P. gingivalis</i> + <i>P. nigrescens</i>	3.2	0.01
	<i>P. gingivalis</i> + <i>P. nigrescens</i> + <i>T. denticola</i>	2.6	0.05
	<i>P. gingivalis</i> + <i>T. forsythia</i> + <i>P. nigrescens</i>	3.2	0.01
	Periodontitis severity	4.7	0.03

\*Adapted from Contreras et al. (31).

protective and tissue-destructive effects, depending upon the type of the infectious agent and the immune competency of the individual. Features of herpesviral and bacterial infections of importance in the etiopathogeny of periodontitis are highlighted below.

## General overview

Infectious agents causing periodontitis must be able to colonize periodontal sites, overcome local host defenses, proliferate in periodontal sites and participate in the breakdown of periodontal tissues (192). Also, periodontitis develops in a multistep process that reflects the dynamic interplay between the periodontal infectious agents and the host immune responses.

Successful immune control of a periodontal infection depends on a highly coordinated series of host defenses (36). The host identifies pathogens as nonself by recognizing pathogen-associated molecular patterns (116). Pathogen recognition receptors and signaling pathways subsequently activate cells of the immune system. Cytokines mediate the interaction and regulation of immune cells. Optimally, the host executes immune responses sufficient to control the pathogens, but also ensures suppression of excessive immune reactions in order to limit the pathological consequences of inflammation. If

uncoordinated, the host immune response by itself may cause pathosis.

Immune regulation is mediated by activated CD4 T cells, which, on the basis of characteristic cytokine profiles, are grouped into T helper (Th) type 1 (Th1), Th2, Th17 and induced T regulatory (iTreg) cells (52). Activated T helper cells secrete either pro- or anti-inflammatory cytokines depending on the type and the mode of the immunologic stimulus. Th1 cells drive the type-1 pathway ('cellular immunity') to fight enveloped viruses and intracellular bacterial pathogens, eliminate cancerous cells and stimulate delayed-type hypersensitivity reactions (93). Activated Th1 cells are characterized as pro-inflammatory and are a source of interferon-gamma, interleukin (IL)-1, IL-2, IL-6, IL-12, IL-18, IL-23 and tumor necrosis factor-alpha. Cytomegalovirus and other herpesviruses induce Th1-type pro-inflammatory cytokine responses (163). Pro-inflammatory cytokines/chemokines promote leukocyte infiltration into the site of infection and play a crucial role in orchestrating the immune response against herpesvirus infections by enhancing the proliferation of T lymphocytes and facilitating cell–cell signaling.

Th2 cells induce the type-2 pathway ('humoral immunity'), which is linked to differentiation of B cells and antibody production (93). Antibodies are of critical importance in the defense against nonenveloped viruses and extracellular bacterial pathogens.



The Th2 response evokes the secretion of the anti-inflammatory and immunoregulatory cytokine IL-10, and of IL-4, IL-5, IL-6, IL-9 and IL-13.

However, the Th1/Th2 concept has inconsistencies, and several human and animal cytokine activities fail to fall into exclusive Th1 or Th2 patterns (93). IL-6 can act as both a pro-inflammatory and an anti-inflammatory cytokine. Also, the various cytokines in inflammation have both unique and redundant roles, and can augment or inhibit the effect of other cytokines, complicating the assessment of the biological significance of individual cytokines. In addition, Th1 cells can inhibit Th2 cell differentiation by their expression of interferon-gamma and IL-12, while Th2 cells can inhibit Th1 cells by their expression of IL-4, IL-10 and transforming growth factor-beta (233). The balance between Th1 and Th2 immune responses is regulated by iTreg cells and influenced by genetic and environmental factors. The feedback mechanisms among Th1 and Th2 type cytokines aim at amplifying or dampening local inflammatory responses in order to sustain an adequate host response and to safeguard the host from bursts of exaggerated inflammation.

Th1 and Th2 cell responses have received considerable interest in periodontal research (55, 71). As Th1 and Th2 immune responses are partly antagonistic to each other, the net effect of the combined Th1/Th2 immune response may determine whether a periodontal infection leads to limited gingival tissue reaction or to breakdown of periodontal attachment. Pro-inflammatory cytokines occur at elevated levels in severe periodontitis lesions (62), where they exert immunomodulating activity as well as participate in collagen degradation and bone resorption (92). As periodontitis lesions concurrently harbor herpesviruses (which trigger Th1-based cellular immunity) and pathogenic bacteria (which induce Th2-based humoral immunity), the diseased periodontium may experience a changing dominance of either herpesviral or bacterial immunity.

Some studies have suggested that Th1 cells are associated with stable periodontitis and that Th2 cells are associated with disease progression (56, 186). Other studies have reported a predominance of Th1 cells, or a reduced Th2 response, in diseased periodontal tissue (55, 56, 216). These findings are not necessarily in conflict with each other. A predominance of Th1 cells in disease-stable sites may suggest a successful anti-herpesvirus defense, and elevated levels of Th1 cells in progressing lesions may reflect an ongoing effort by the host to control an active herpesvirus infection. Similarly, the dis-


pute about a dominance of either T cells or B cells in periodontitis sites may be partly unfounded (11, 71). A preponderance of T cells may reflect the attempt of the host to control an active herpesvirus infection. High B-cell counts may be caused by specific antibody production or the result of an active Epstein–Barr virus infection, which, in the absence of sufficient cytotoxic T-cell function, can induce B-cell proliferation by polyclonal stimulation (21).

## Herpesviruses

The eight human members of the herpesvirus family infect parenchymal cells, connective tissue cells, epithelial cells, various hematopoietic cells and other cell types, and can cause a variety of illnesses by mechanisms that are direct, indirect or immunoregulatory (151, 189, 190). The clinical outcome of herpesvirus infections ranges from subclinical or mild disease to encephalitis, pneumonia and other potentially lethal infections, and even to cancer, including lymphoma, sarcoma and carcinoma (190). The great majority of adults are carriers of Epstein–Barr virus and cytomegalovirus. Once infected, a person harbors the herpesvirus for life.

The herpesvirus replication-cycle includes binding of viral envelope glycoproteins to cell-membrane receptors, internalization and dismantling of the virus particle, migration of the viral DNA to the cell nucleus, transcription of viral genes, assembly of the virion and viral egress from the infected cell (Fig. 1). Herpesviruses destroy infected cells by active lytic replication. After primary infection, herpesviruses remain latent with limited expression of viral genes, albeit retaining the transcriptional and replicational capacity. Latency/persistence is maintained for Epstein–Barr virus in resting memory B lymphocytes, and for human cytomegalovirus in dendritic cells and in monocytes and their progenitors.

Active herpesvirus infections evoke strong innate and adaptive immune responses, which include both immune activation and immune suppression (34, 131, 164). Key effector cells of the innate immune system are dendritic cells, monocytes/macrophages and natural killer cells, whose function is to limit the viral burden until cells of the adaptive immunity become available to suppress the infection. The effector cells recognize viral proteins via toll-like receptors, natural killer cell receptors or other pattern recognition receptors. Herpesvirus DNA reacts with toll-like receptor 9, which is significantly up-regulated in periodontitis lesions compared with gingivitis



**Fig. 1.** Schematic representation of herpesvirus replication. A herpesvirus virion initiates infection by fusing specific viral glycoproteins on the viral envelope with cellular receptors on the cell surface. After entering the cytoplasm, capsid is transported to the nuclear pore where viral DNA is released into the nucleus. Viral transcription and translation occur in 3 phases; immediate early, early, and late. Immediate early proteins are involved in viral transcriptional regulation and in mobilizing the cellular transcriptional machinery. Early proteins facilitate viral DNA replication. Late proteins are structural proteins of the virus that form empty capsids. Viral DNA is packaged into pre-formed capsids in the nucleus. Viral glycoproteins and tegument proteins are incorporated into the cellular membrane and capsids become enveloped to form virions. Virions are transported via the endoplasmic reticulum, and infectious virions can either remain cell associated, spread to uninfected cells via virus-induced fusion, or can be released from the cell by exocytosis or by cell lysis.

lesions (88). Cells of innate immunity employ cytokine secretion and cell-mediated cytotoxicity as the primary anti-herpesvirus effector mechanisms. Macrophages and polymorphonuclear leukocytes can destroy antibody-coated virions or virus-infected cells via reactive oxygen species, nitric oxide and activated caspases. Natural killer cells are an important source of interferon-gamma and are able to kill herpesvirus-infected cells via virus-specific antibody-dependent cell-mediated cytotoxicity or via antibody-independent mechanisms. In addition, natural killer cells share similarities with cytotoxic T cells and may play a role in adaptive immunity (206).

The phagocytic cells internalize, process and express herpesvirus-derived immunogenic peptides on their surface which, after linkage to major histocompatibility complex (MHC) molecules, can attach to and activate Th1 cells of the adaptive immune system. Cytomegalovirus can have a profound influ-

ence on the immune system of healthy individuals (25), and cytomegalovirus reactivity has been detected in as many as 30–50% (up to 80%) of the T cells of cytomegalovirus-seropositive elderly individuals (200). Recognition of the herpesvirus proteins causes the induction of the pro-inflammatory transcription factor nuclear factor-kappaB (NF- $\kappa$ B) with a subsequent release of cytokines and mobilization of CD8<sup>+</sup> T cells (116). Activated CD8<sup>+</sup> T cells differentiate into virus-specific cytotoxic T cells capable of recognizing and killing cells carrying viral peptides. The release of CD8<sup>+</sup> T-cell-associated antiviral cytokines, such as interferon-gamma and tumor necrosis factor-alpha, may also inhibit viral replication without killing the infected cell (66).

Herpesvirus infections in immunocompetent individuals also induce antibody production against herpesvirus proteins (209), and patients with periodontitis exhibit an elevated level of antibodies against

herpesviruses (77, 88). However, antibodies against herpesviruses and against many other enveloped viruses do not ensure a favorable clinical outcome.

Herpesviruses have developed strategies to down-regulate antiviral host defenses in order to persist in the midst of intense inflammation (154). Immunosuppression may thus take place, even in the presence of a substantial immune activation. Herpesviruses encode immunoevasive glycoproteins that interfere with antigen presentation, T-cell immune surveillance and natural killer cell function (130). The viral proteins seek to alter or mimic MHC protein function, leukocyte activation and migration, induction and activity of cytokines and interferons, antibody-based defense mechanisms, and host cell susceptibility to apoptosis (programmed cell death), which is the principal mode of physiologic elimination of cells (130).

Despite elaborate immune-evasion efforts by herpesviruses, the host immune system generally prevails in immunocompetent subjects, perhaps because of the host immune-sensing mechanisms that terminate viral gene expression before the assembly of infectious virions (161). However, herpesvirus disease incidence is elevated in immunologically immature subjects, and in individuals who are immunosuppressed as a result of advancing age (immunosenescence), diseases [e.g. HIV/acquired immune-deficiency syndrome (AIDS)] or treatments (e.g. cancer chemotherapy, radiotherapy, pharmacological immunosuppression with organ transplantation, high-dose corticosteroids).

## Bacteria

Bacterial infections evoke functionalities of both the innate immune system and the adaptive immune system. Bacterial species attach to specific toll-like receptors to establish some degree of specificity in the innate immune system and subsequently in the adaptive immune system (76, 94). Bacterial pathogens detected by toll-like receptors on the surface of macrophages activate NF- $\kappa$ B-mediated transcription of cytokines and chemokines (136). Macrophage-released cytokines and chemokines recruit neutrophils in the innate immune system and serve as antigen-presenting cells for lymphocytes in the adaptive immune system.

Neutrophils comprise more than 90% of the inflammatory cells in periodontal pockets (45). Their importance in periodontal defense is evidenced by the observation of severe periodontitis in most subjects exhibiting major neutrophil deficiencies (38).

Neutrophils phagocytize and kill ingested bacteria by means of reactive oxygen species (e.g. the myeloperoxidase system and hypochlorite), antimicrobial proteins (e.g. defensins, lysozyme and lactoferrin), degradative enzymes (e.g. elastase and cathepsin G) and other microbicidal pathways (38).

Extracellular pathogenic bacteria activate Th2 cells, which release anti-inflammatory cytokines and commit B cells to antibody production. *P. gingivalis* seems to evoke primarily a Th2-type response in periodontitis patients (79). Antibacterial antibodies of the IgG1 subclass play important roles in opsonization and complement activation (38). Lipopolysaccharide of *P. gingivalis* and of other periodontopathic bacteria can also activate complement via the alternative pathway and induce the release of pro-inflammatory cytokines (41). Complement assists antibodies by acting as an opsonin, by lysing bacterial cells and by attracting lymphocytes and neutrophils to the site of infection.

Intracellular bacteria trigger a Th1-mediated immune response, which includes the release of interferon-gamma, pro-inflammatory cytokines and the IgG2 antibody isotype (48, 220). IgG2 serum antibody occurs at high levels in patients with localized aggressive (juvenile) periodontitis and, despite being a less efficient opsonin than IgG1 and IgG3, seems to protect against further tissue destruction (181). *P. gingivalis* (101, 106), *A. actinomycetemcomitans* (26, 169) and other periodontal species (27, 222, 225) have the ability to invade cells of the periodontium and thus may trigger a Th1, as well as a Th2, immune response. *P. gingivalis*-specific T cells can produce both Th1 and Th2 cytokines irrespectively of the type of antigen-presenting cells (54).

## Pathogenic interactions among infectious agents in periodontal diseases

Epstein–Barr virus–cytomegalovirus co-infection tends to be associated with severe types of oral disease, including aggressive periodontitis (89, 179, 219, 239), chronic periodontitis (22, 235), periodontal abscesses (180), acute necrotizing ulcerative gingivitis (30), symptomatic peri-apical lesions (194) and oral ulcers (210). Cytomegalovirus–herpes simplex virus co-infection has also been associated with increased gingival inflammation and periodontal attachment loss (110). Persons exhibiting a high rate of shedding of Epstein–Barr virus into saliva tend to reveal sali-

vary cytomegalovirus DNA more often than those with a low rate of Epstein–Barr virus shedding, which may be suggestive of a cooperative relationship between the two viruses (64). Infants and children infected with both Epstein–Barr virus and cytomegalovirus have shown stronger T-cell responses and more severe disease than children mono-infected with either of the viruses (226). Feline calicivirus and feline herpesvirus were both shed in 88% of cats with chronic gingivostomatitis compared to 21% of cats without chronic oral inflammatory disease (112).

A concomitant infection with two herpesviruses may activate latent viral genomes by the mechanism of reciprocal transactivation, which connotes that gene products of one virus trigger the transcription of another virus (231). Two active viruses, each providing their own unique set of virulence factors, can result in a particularly severe disruption of the immune system and accelerate a disease process (213). Herpesvirus re-activation causes a major spike in cytotoxic T cells and pro-inflammatory cytokines (132), but also produces virus-derived homologues of human IL-10 (108) and other inhibitors of the antiviral Th1 cell-mediated defense (195). Cytomegalovirus IL-10 suppresses NF- $\kappa$ B activation and subsequently transcription of tumor necrosis factor- $\alpha$  and IL-1 $\beta$  (135). Specific genotypes of IL-10 are correlated with an increased risk of progressive periodontitis (35). Other mechanisms of interaction between two viruses include the enhanced expression of viral receptors and co-receptors in target cells as well as the production of superantigens (120).

Herpesviruses and specific bacteria in aggregate are also associated with enhanced severity of periodontal disease (179). Herpesviruses may aid in the initial colonization and upgrowth of periodontopathic bacteria. An active human cytomegalovirus infection of primary periodontal pocket epithelial cells or HeLa cells enhances the adherence of *A. actinomycetemcomitans* in a dose-dependent mode (217); viral infections may destroy epithelial cells and expose new bacterial attachment sites in the basement membrane; and herpesvirus glycoproteins expressed on the surface of infected host cells may serve as receptors for bacteria. In addition, as *A. actinomycetemcomitans* can bind to the Fc part of the IgG molecule (221), the organism may attach to antibodies directed against the herpesvirus-derived glycoproteins. Consistent with the concept of herpesviral–bacterial synergism, the initial phases of localized aggressive (juvenile) periodontitis demonstrate an active cytomegalovirus infection (219) and a remarkable increase in *A. actinomycetemcomitans*

subgingival counts (197). Cytomegalovirus has, in several animal models, shown the ability to impair neutrophil chemotaxis, phagocytosis, oxidative burst and intracellular killing capacity (2); some of these neutrophil defects have also been described in localized aggressive periodontitis (182). Individuals who show an absence of herpesviral infection or of herpesviral re-activation may exhibit a normal periodontium or minimal or nonprogressive disease, even in the presence of periodontopathic bacteria.

Herpesviruses can compromise the immune control of periodontopathic bacteria by a variety of mechanisms. Polymorphonuclear leukocytes seem to exhibit less efficient chemotaxis and bactericidal capacity in periodontitis patients with subgingival herpesviruses than in herpesvirus-free subjects (142). Anti-herpesvirus cytotoxic/suppressor T cells, which are present at elevated levels in aggressive periodontitis lesions (187), may adversely affect mammalian cells involved in the antibacterial periodontal defense. Th1 cytokines associated with active herpesvirus infections reduce Th2-cell responses and thereby the antibody-mediated control of pathogenic bacteria. Herpesviruses are capable of subverting macrophage (51, 63, 109), complement (111) and neutrophil (1) functions of importance in the antibacterial host defense. *P. gingivalis* and other exogenous-like species, which may be primarily controlled by antibody-mediated mechanisms (159, 215), may benefit most from a reduction in antibacterial immunity and outgrow co-existing indigenous microorganisms. Taken together, an active herpesvirus infection has the potential to impair antibacterial host defenses and may trigger a microbial shift towards a more virulent subgingival microbiota.

The lipopolysaccharide of gram-negative periodontopathic bacteria, most prominently *P. gingivalis*, can induce a Th1-cell type release of pro-inflammatory cytokines (41, 223), and may co-operate with cytomegalovirus in stimulating IL-1 $\beta$  gene transcription (229). As Th1 cell activities can inhibit Th2 antibacterial immunity, the lipopolysaccharide-induced Th1 cell response may partly constitute an immune-evasive maneuver by periodontopathic bacteria in their efforts to survive in a hostile environment. On the other hand, the Th1 immune response may help to control *P. gingivalis* infections when they occur intracellularly (101, 106). Also, as herpesviruses may induce the overgrowth of *P. gingivalis* and other pathogenic species (179, 193, 196), the Th1-mediated anti-herpesvirus immune response may indirectly aid in containing the population of periodontopathic bacteria.



It is equally conceivable that a bacterial infection can pave the way for a herpesvirus clinical infection. *P. gingivalis* sonicate has the potential to re-activate Epstein–Barr virus (205). The etiopathogenic model for periodontitis, detailed below, proposes that a bacterial–viral–bacterial sequential infection gives rise to the disease. Dental biofilm bacteria initiate gingivitis with an influx of herpesvirus-infected monocyte/macrophages, T cells or B cells (32). A subsequent immunosuppressive event may then re-activate latent herpesviruses, resulting in the release of pro-inflammatory cytokines and matrix metalloproteinases, and in the overgrowth of periodontopathic bacteria.

Proteolytic enzymes of periodontal bacteria can degrade pro-inflammatory cytokines and other host-defense systems (83, 212), thereby potentially activating a co-existing latent herpesvirus infection. Human gingival epithelial cells challenged with *P. gingivalis* showed a fourfold increase in the primary cytokine IL-1 $\beta$  level, but the related secondary cytokines IL-6 or IL-8 were virtually undetectable as a result of direct degradation by *P. gingivalis* proteases, with lysine gingipain being the most effective (202). Thus, in addition to subverting host defenses against bacterial infections (153), gingipains may exert periodontopathogenicity by perturbing cytokine-mediated antiviral host responses.

Lastly, herpesviruses and bacteria may interact bidirectionally, as shown in a study of infected wound chambers in mice (203), adding another level of complexity to the analysis of the pathophysiology of periodontitis. Mice co-infected with murine cytomegalovirus and *P. gingivalis* in wound chambers exhibited significantly higher mortality than mice infected with either murine cytomegalovirus or *P. gingivalis*, or simultaneously with murine cytomegalovirus and *E. coli* (203). The increase in cytomegalovirus pathogenicity was related to an ability of *P. gingivalis* to suppress interferon-gamma, perhaps because of the proteolytic activity of the organism. A low level of interferon-gamma was found despite the capacity of cytomegalovirus to trigger the induction of interferon-gamma, and despite the ability of bacterial lipopolysaccharide, via cytokine stimulation, to induce interferon-producing CD8<sup>+</sup> T cells (160). Adding further to the complexity, cytomegalovirus encodes genes capable of inhibiting the interferon response and antiviral processes (37).

In teleological terms, periodontitis can perhaps be viewed as a by-product of the efforts by the host to

control periodontal herpesvirus infections and avoid systemic viral diseases. Periodontal pro-inflammatory cytokines, in spite of being capable of inducing collagen degradation and alveolar bone resorption (92), may actually be overall beneficial by helping to prevent activation and systemic dissemination of virulent viruses (65). Similarly, although CD8<sup>+</sup> T cells may impede antibacterial defenses, they also confer a critical antiviral function. Periodontitis may represent an excellent example of how host immune responses can exert simultaneously protective and destructive functionalities.

## Herpesviral–bacterial model of periodontitis

The finding of abundant herpesviruses in periodontitis lesions redefines the pathogenic paradigm of the disease. Fig. 2 describes a model for the development of periodontitis, which as its core has a sequential infectious process that proceeds from bacteria to herpesvirus to bacteria (191). Initially, bacteria in the dental biofilm induce gingivitis, which permits latent herpesviruses, embedded in the DNA of macrophages, T lymphocytes and B lymphocytes, to infiltrate the periodontium (32). Cytomegalovirus can replicate in gingival tissue (68), which may help to sustain the periodontal infection. Re-activation of the latent herpesviruses may occur spontaneously or during periods of decreased host defense, resulting from drug-induced immunosuppression, concurrent infection, unusual and prolonged emotional stress, hormonal changes, physical trauma, etc. Probably not coincidentally, most herpesvirus-activating factors are also suspected risk factors/indicators for periodontitis (162).

In response to the active herpesvirus infection, the host elicits a robust T-cell-mediated immune response, comprised primarily of CD8<sup>+</sup> T cells. To counteract the hostile host environment, herpesviruses in turn execute strategies to down-regulate antiviral host defenses. Herpesviruses evade immune responses by disintegrating components of the MHC and interfering with antigen presentation, by silencing natural killer cells, by expressing a viral homolog of IL-10, by diverting potent cytokine responses and by inhibiting apoptosis (189). The encounter between antiviral host defenses and virally mediated anti-host responses results in a major release of pro-inflammatory cytokines that have the potential to activate osteoclasts (13, 71) and to impair antibody-mediated host defenses against exogenous-like bacterial spe-






Fig. 2. Herpesviral-bacterial model of periodontitis.

cies, such as *P. gingivalis* and *A. actinomycetemcomitans* (179). The ensuing increase in pathogenic bacteria provides additional mechanisms of periodontal tissue destruction (78).

Cytomegalovirus or other herpesviruses can exert acute cytopathogenic effects on fibroblasts, epithelial cells, keratinocytes, endothelial cells, inflammatory cells and bone cells (17). An active herpesviral infection in severely immunocompromised patients may directly destroy periodontal cells and tissue by cytotoxic mechanisms, as seen in patients with necrotizing ulcerative gingivitis and noma. Herpesvirus

infections may participate in oral collagen degradation, as suggested in *in vivo* (172) and *in vitro* (14) studies, and potentially interfere with periodontal tissue turnover and healing. Herpesvirus infections have also been related to diminished repair in periodontal guided tissue regeneration (199) and to dry socket formation after tooth extraction (73, 74).

In the herpesviral-bacterial model of periodontitis, herpesvirus-related cytopathogenic effects, immune evasion, immunopathogenicity, latency, re-activation from latency and tissue/site tropism comprise important aspects of periodontal pathosis. It is likely

that the early stages of periodontitis in immunologically naïve hosts involve an active herpesviral infection that primarily causes cytopathogenic effects, whereas most clinical manifestations in immunocompetent individuals are secondary to cellular or humoral immune responses. The proposed model may help to clarify at least some of the clinical features of periodontitis (179, 189). The propensity for site tropism of herpesviruses may explain why periodontal tissue destruction can differ markedly from tooth-to-tooth in the same patient or from surface-to-surface in individual teeth. A vigorous anti-herpesvirus host defense may ensure a prolonged period of periodontal stability, even in the presence of virulent bacteria. Herpesvirus re-activation from the state of latency may trigger a burst of periodontal tissue damage and progressive disease. However, most immunocompetent individuals experience episodes of oral herpesvirus re-activation lasting only a few hours or a few days (119), which is probably too short a time span to initiate or aggravate clinical periodontal disease.

## Therapeutic implications

Conventional periodontal therapy can reduce the periodontal load of herpesviruses. Mechanical debridement has suppressed subgingival Epstein–Barr virus to undetectable levels in 12 of 21 patients (234), and has decreased subgingival Epstein–Barr virus genome-copies by sixfold and subgingival cytomegalovirus genome-copies by 38-fold (177). After repeated debridement, 24 patients with periodontitis yielded no cytomegalovirus, but were found to have Epstein–Barr virus and herpesvirus-7 (168), suggesting that cytomegalovirus is particularly susceptible to the effects of periodontal therapy. In a patient with Papillon–Lefèvre syndrome, mechanical debridement and systemic amoxicillin–metronidazole suppressed subgingival Epstein–Barr virus, cytomegalovirus and *A. actinomycetemcomitans* to undetectable levels and prevented further loss of periodontal attachment (143). The decrease in post-treatment herpesvirus counts is probably caused by a reduction in gingivitis and thus in the numbers of virally infected inflammatory cells. Similarly, the low herpesvirus counts in healthy periodontal sites are probably the result of a virtual absence of infected inflammatory cells. Cytomegalovirus was also not detected in healthy peri-implant sites (139).

Saliva can contain high genome-copy counts of herpesviruses. Medically healthy persons have been

shown to contain  $3.6 \times 10^2$  to  $1.6 \times 10^9$  copies/ml of Epstein–Barr virus in saliva (173) and from 6 to  $2.2 \times 10^6$  per 0.5 µg of DNA (228). Salivary cytomegalovirus DNA was detected in one-half of periodontitis patients at levels of  $3.3 \times 10^3$ – $4.2 \times 10^4$  copies/ml, whereas the virus was not detected in the saliva of periodontally normal individuals or in complete denture wearers (173), affirming the close relationship between cytomegalovirus and periodontitis. Herpesvirus-6 and herpesvirus-7 can occur in saliva with prevalences exceeding 90% and in concentrations of several million genome-copies (126). Herpesvirus-6 was detected in the whole saliva of 68% of healthy volunteers from Brazil (152). Herpesvirus-8 reached salivary loads of  $2.6$ – $4.1 \times 10^6$  genome-copies/ml in a renal allograft recipient (4). HIV-infected individuals harbor higher salivary cytomegalovirus counts than non-HIV-infected persons (114, 115), and HIV-infected individuals receiving antiretroviral therapy demonstrate higher salivary prevalence and copy counts of Epstein–Barr virus and other herpesviruses than normal control subjects (127). HIV-infected individuals have revealed salivary median copy counts of  $5.3 \times 10^5$ /ml for Epstein–Barr virus and  $3.3 \times 10^3$ /ml for cytomegalovirus (64).

Conventional periodontal treatment has reduced salivary Epstein–Barr virus genome-copy counts by 13-fold and salivary cytomegalovirus copy counts by 65-fold (177), salivary Epstein–Barr virus counts in two children with Kostmann syndrome by more than 100-fold (241) and the average Epstein–Barr virus counts per ml of saliva from 946,000 to 9,010; moreover, six of 11 (54%) study patients with salivary Epstein–Barr virus pretreatment did not have the virus post-treatment (81). Several patients in the above studies exhibited gingival inflammation post-treatment; more efficacious anti-gingivitis measures may have decreased the salivary herpesvirus counts even further (188). These treatment data suggest that diseased periodontal sites are an important source of salivary herpesviruses. The potential of periodontal therapy to decrease herpesvirus levels in saliva may reduce the risk of herpesvirus transmission and herpesvirus-related diseases among close acquaintances.

The herpesviral–bacterial model of periodontitis provides a rationale for considering new approaches to disease prevention and treatment. Sunde et al. (208) treated a patient, who exhibited refractory periodontitis and high Epstein–Barr virus subgingival copy counts, with the anti-herpesvirus drug, valacyclovir HCl, 500 mg twice a day for 10 days. The

treatment suppressed subgingival Epstein–Barr virus to undetectable levels for at least 1 year and resulted in a ‘dramatic’ clinical improvement (208). Sunde et al. (208) proposed employing virus screening in periodontal treatment to determine when antiviral intervention is appropriate and if it has succeeded. Periodontal viruses may be identified successfully by using diagnostic DNA microarrays that are able to detect simultaneously herpes simplex virus types 1 and 2, Epstein–Barr virus, and cytomegalovirus as well as other viruses (134); or by using multiplex real-time PCR techniques to quantify simultaneously the number of genome-copies of herpes simplex virus, varicella–zoster virus, Epstein–Barr virus, cytomegalovirus and human herpesvirus-6 (49, 67).

Anti-herpesvirus chemotherapy can also decrease the salivary viral load. A short course of valacyclovir, 2 g twice on the day of treatment and 1 g twice the following day, resulted in a significant decrease in the salivary occurrence of Epstein–Barr virus compared with controls (126). Valacyclovir, 500 mg orally twice daily for 1 month, given to elite male distance runners, reduced the salivary load of Epstein–Barr virus by 82% compared with placebo (33). Valacyclovir therapy, 3 g per day for 14 days, resulted in a reduction, of more than 100-fold, of Epstein–Barr virus genome-copies in oral wash fluid of patients with acute infectious mononucleosis (9).

Chemotherapeutics are effective against viruses in the lytic phase, but not against viruses in the latent phase, limiting their potential use to disease-active infections. Acyclovir types of drugs are acyclic nucleoside analogues that inhibit herpesviral DNA polymerase and replication of the viral genome. The orally administered acyclovir prodrug, valacyclovir, can reach serum concentrations similar to those of intravenously administered acyclovir and is prescribed for a variety of herpesviral diseases (149). Prolonged treatment with valacyclovir at dosages of 500–1000 mg/day is well tolerated, perhaps except in immunosuppressed individuals, and the adverse events are infrequent and generally mild, with headache being reported most often (6). To date, resistance to valacyclovir has not been clinically significant. However, randomized controlled trials are needed before anti-herpesviral chemotherapy can be considered as standard clinical practice in the treatment of advanced periodontitis.

Future management of periodontal diseases may benefit from anti-herpesviral immunotherapeutics: either prophylactic vaccines, which harness the immune system of healthy subjects to prevent

infection with disease-causing viruses; or therapeutic vaccines, which stimulate the immune system into combating existing viruses and disease. An efficacious vaccine against herpesviruses may also provide clinical proof-of-principle of the periodontopathic importance of the viruses. The notion of herpesviral–bacterial synergism in periodontitis implies that vaccination against herpesviruses can also contribute to the control of periodontopathic bacteria. One difficulty to overcome with prophylactic vaccination is declining immunity over time, which carries an increased risk of delayed-onset primary herpesvirus diseases with increased morbidity. The US Institute of Medicine has assigned high priority to the development of vaccines against herpes simplex virus, Epstein–Barr virus and cytomegalovirus, to be given to 12-year-old children (204).

## Summary

The etiopathogenesis of periodontitis includes virulence factors of herpesviruses and bacteria, host immune responses against viral and bacterial infections, and manipulation of host-cell processes by the infectious agents. Herpesviruses may induce periodontitis by activating specific tissue-destroying pathways of the immune system and by predisposing an individual to bacterial carriage or increased bacterial load. However, the molecular contribution of herpesviruses versus bacteria to periodontal pathosis remains little understood.

The inflamed periodontium appears to be a major site for Epstein–Barr virus and cytomegalovirus accumulation and re-activation, especially in the progressive phase of periodontal disease. A single advanced periodontitis lesion may contain up to 100 million genomic copies of herpesviruses, approaching the total viable counts of bacteria. Immunosuppressive factors are potential triggers of herpesvirus re-activation and, perhaps for that reason, are also major risk factors for periodontitis. An active herpesvirus infection in the periodontium may give rise to systemic viremia, but the magnitude and duration of this are unknown.

An active herpesvirus infection correlates with periodontitis disease activity and may be a major contributor to the periodontal immune response. Herpesviruses are potent inducers of pro-inflammatory cytokines that have the potential to activate osteoclasts and matrix metalloproteinases. An active herpesvirus infection can also impair antibacterial immune mechanisms and potentially cause an

upgrowth of periodontopathic bacteria. Some periodontopathic bacteria may re-activate a latent herpesvirus infection. Synergism among herpesviruses and bacteria may play an important role in the onset and progression of periodontitis. The interplay of herpesviruses and bacteria in periodontitis may be compared to a marionette theater where the puppeteer is the virus and the puppets are the bacteria. Even if the puppeteer (virus) controls the performance (disease), both the puppeteer and the puppets are necessary for the marionette theater to function.

Obviously, it is difficult to link a herpesvirus infection that occurs in childhood to periodontitis that debuts several decades later. An important question is whether the herpesvirus–periodontitis association is etiologically based or is merely an epiphenomenon to gingival inflammation. Studies on herpesviral etiology of medical diseases face similar difficulties in delineating cause and effect. To distinguish between causality and correlation, information is needed on the extent to which an active herpesvirus infection gives rise to destructive periodontal disease, and the extent to which disease-active periodontitis may activate a latent herpesvirus infection. A causal relationship may be inferred if the removal of herpesviruses by specific antiviral medication arrests, reverses or prevents periodontitis. Studies assessing temporal and histological correlations may also help to elucidate the role of herpesviruses in periodontal disease. Such studies may take advantage of molecular techniques able to quantify herpesvirus loads and relate either active or latent herpesvirus infection to periodontitis-disease activity. However, the definitive answer to the periodontopathic significance of herpesviruses will probably have to await the development of efficacious anti-herpesvirus vaccines.

The notion of a herpesviral–bacterial co-infection in periodontitis may turn out to be the pathogenic Rosetta stone that unlocks many of the intricacies of the disease. Herpesvirus-induced periodontitis implies that anti-herpesvirus immunity constitutes an important aspect of achieving a long-lasting state of stable periodontal conditions. The development of herpesvirus vaccines in the not too distant future makes the topic of periodontopathic herpesviruses particularly intriguing. Control of herpesviruses by vaccination may foreshadow a future with a diminishing role for the traditional periodontal therapies of surgery and antibiotics. It is hoped that the issues raised in this review will help to steer periodontal research into new fertile fields of investigation.

## References

1. Abramson JS, Mills EL. Depression of neutrophil function induced by viruses and its role in secondary microbial infections. *Rev Infect Dis* 1988; **10**: 326–341.
2. Abramson JS, Wheeler JG. Virus-induced neutrophil dysfunction: role in the pathogenesis of bacterial infections. *Pediatr Infect Dis J* 1994; **13**: 643–652.
3. Adjei AA, Armah HB, Gbagbo F, Boamah I, Adu-Gyamfi C, Asare I. Seroprevalence of HHV-8, CMV, and EBV among the general population in Ghana, West Africa. *BMC Infect Dis* 2008; **8**: 111.
4. Al-Otaibi LM, Al-Sulaiman MH, Teo CG, Porter SR. Extensive oral shedding of human herpesvirus 8 in a renal allograft recipient. *Oral Microbiol Immunol* 2009; **24**: 109–115.
5. Alho OP. Viral infections and susceptibility to recurrent sinusitis. *Curr Allergy Asthma Rep* 2007; **5**: 477–481.
6. Bakaletz LO. Viral potentiation of bacterial superinfection of the respiratory tract. *Trends Microbiol* 1995; **3**: 110–114.
7. Bakaletz LO. Otitis media. In: Brogden KA, Guthmiller JM editors. *Polymicrobial diseases*. Washington, DC: American Society for Microbiology, 2002: 259–298.
8. Baker DA, Blythe JG, Miller JM. Once-daily valacyclovir hydrochloride for suppression of recurrent genital herpes. *Obstet Gynecol* 1999; **94**: 103–106.
9. Balfour HH Jr, Hokanson KM, Schacherer RM, Fietzer CM, Schmeling DO, Holman CJ, Vezina HE, Brundage RC. A virologic pilot study of valacyclovir in infectious mononucleosis. *J Clin Virol* 2007; **39**: 16–21.
10. Barton ES, White DW, Cathelyn JS, Brett-McClellan KA, Engle M, Diamond MS, Miller VL, Virgin HW IV. Herpesvirus latency confers symbiotic protection from bacterial infection. *Nature* 2007; **447**: 326–329.
11. Berglundh T, Donati M, Zitzmann N. B cells in periodontitis: friends or enemies? *Periodontol 2000* 2007; **45**: 51–66.
12. Boeckh M, Nichols WG. Immunosuppressive effects of beta-herpesviruses. *Herpes* 2003; **10**: 12–16.
13. Botero JE, Contreras A, Parra B. Profiling of inflammatory cytokines produced by gingival fibroblasts after human cytomegalovirus infection. *Oral Microbiol Immunol* 2008; **23**: 291–298.
14. Botero JE, Contreras A, Parra B. Effects of cytomegalovirus infection on the mRNA expression of collagens and matrix metalloproteinases in gingival fibroblasts. *J Periodontol Res* 2008; **43**: 649–657.
15. Botero JE, Parra B, Jaramillo A, Contreras A. Subgingival human cytomegalovirus correlates with increased clinical periodontal parameters and bacterial coinfection in periodontitis. *J Periodontol* 2007; **78**: 2303–2310.
16. Botero JE, Vidal C, Contreras A, Parra B. Comparison of nested polymerase chain reaction (PCR), real-time PCR and viral culture for the detection of cytomegalovirus in subgingival samples. *Oral Microbiol Immunol* 2008; **23**: 239–244.
17. Britt WJ, Alford CA. Cytomegalovirus. In: Fields BN, Knipe DM, Howley PM editors. *Fields Virology*, 3rd edn. Philadelphia: Lippincott-Raven, 1996: 2493–2524.
18. Brook I. The association of anaerobic bacteria with infectious mononucleosis. *Anaerobe* 2005; **11**: 308–311.



19. Brook I. The role of bacterial interference in otitis, sinusitis and tonsillitis. *Otolaryngol Head Neck Surg* 2005; **133**: 139–146.
20. Bulut Y, Karlidag T, Seyrek A, Keles E, Toraman ZA. Presence of herpesviruses in middle ear fluid of children with otitis media with effusion. *Pediatr Int* 2007; **49**: 36–39.
21. Cesarman E. Epstein-Barr virus (EBV) and lymphomagenesis. *Front Biosci* 2002; **7**: e58–65.
22. Chalabi M, Moghim S, Mogharehabet A, Najafi F, Rezaie F. EBV and CMV in chronic periodontitis: a prevalence study. *Arch Virol* 2008; **153**: 1917–1919.
23. Chen V, Chen Y, Li H, Kent K, Baumgartner JC, Machida CA. Herpesviruses in abscesses and cellulitis of endodontic origin. *J Endod* 2009; **35**: 182–188.
24. Chen LL, Sun WL, Yan J, Yu ZS. [Correlation between infection of different glycoprotein B genotypes of human cytomegalovirus and human chronic periodontitis]. *Zhonghua Kou Qiang Yi Xue Za Zhi* 2006; **41**: 212–215 (Chinese).
25. Chidrawar S, Khan N, Wei W, McLarnon A, Smith N, Nayak L, Moss P. Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals. *Clin Exp Immunol* 2009; **155**: 423–432.
26. Christersson LA, Albin B, Zamboni JJ, Wikesjö UM, Genco RJ. Tissue localization of *Actinobacillus actinomycescomitans* in human periodontitis. I. Light, immunofluorescence and electron microscopic studies. *J Periodontol* 1987; **58**: 529–539.
27. Colombo AV, Silva CM, Haffajee A, Colombo AP. Identification of oral bacteria associated with crevicular epithelial cells from chronic periodontitis lesions. *J Med Microbiol* 2006; **55**: 609–615.
28. Combs DR, Reilly EA, Dawson DR III, Avdiushko SA, Danaher RJ, Miller CS. Detection of human cytomegalovirus in dental plaque from individual periodontal sites by real-time polymerase chain reaction. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2008; **106**: 840–844.
29. Connor E, Powell K. Fulminant pneumonia caused by concomitant infection with influenza B virus and *Staphylococcus aureus*. *J Pediatr* 1985; **106**: 447–550.
30. Contreras A, Falkler WA Jr, Enwonwu CO, Idigbe EO, Savage KO, Afolabi MB, Onwujekwe D, Rams TE, Slots J. Human *Herpesviridae* in acute necrotizing ulcerative gingivitis in children in Nigeria. *Oral Microbiol Immunol* 1997; **12**: 259–265.
31. Contreras A, Umeda M, Chen C, Bakker I, Morrison JL, Slots J. Relationship between herpesviruses and adult periodontitis and periodontopathic bacteria. *J Periodontol* 1999; **70**: 478–484.
32. Contreras A, Zadeh HH, Nowzari H, Slots J. Herpesvirus infection of inflammatory cells in human periodontitis. *Oral Microbiol Immunol* 1999; **14**: 206–212.
33. Cox AJ, Gleeson M, Pyne DB, Saunders PU, Clancy RL, Fricker PA. Valtrex therapy for Epstein-Barr virus reactivation and upper respiratory symptoms in elite runners. *Med Sci Sports Exerc* 2004; **36**: 1104–1110.
34. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. *Clin Microbiol Rev* 2009; **22**: 76–98.
35. Cullinan MP, Westerman B, Hamlet SM, Palmer JE, Faddy MJ, Seymour GJ, Middleton PG, Taylor JJ. Progression of periodontal disease and interleukin-10 gene polymorphism. *J Periodont Res* 2008; **43**: 328–333.
36. Cutler CW, Teng YT. Oral mucosal dendritic cells and periodontitis: many sides of the same coin with new twists. *Periodontol 2000* 2007; **45**: 35–50.
37. DeFilippis VR. Induction and evasion of the type I interferon response by cytomegaloviruses. *Adv Exp Med Biol* 2007; **598**: 309–324.
38. Dennison DK, Van Dyke TE. The acute inflammatory response and the role of phagocytic cells in periodontal health and disease. *Periodontol 2000* 1997; **14**: 54–78.
39. Didierlaurent A, Goulding J, Patel S, Snelgrove R, Low L, Bebien M, Lawrence T, van Rijn LS, Lambrecht BN, Sirard JC, Hussell T. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. *J Exp Med* 2008; **205**: 323–329.
40. Ding F, Feng XH, Meng HX, Zhao YB, Zhang L, Lu RF, Chen ZB. Relationship between herpesviruses and periodontal pathogenic bacteria in subgingival plaque. *Beijing Da Xue Xue Bao* 2008; **40**: 318–322 (Chinese).
41. Dixon DR, Bainbridge BW, Darveau RP. Modulation of the innate immune response within the periodontium. *Periodontol 2000* 2004; **35**: 53–74.
42. Djuric M, Jankovic L, Jovanovic T, Pavlica D, Brkic S, Knezevic A, Markovic D, Milasin J. Prevalence of oral herpes simplex virus reactivation in cancer patients: a comparison of different techniques of viral detection. *J Oral Pathol Med* 2009; **38**: 167–173.
43. Dowd JB, Aiello AE, Alley DE. Socioeconomic disparities in the seroprevalence of cytomegalovirus infection in the US population: NHANES III. *Epidemiol Infect* 2008; **16**: 1–8.
44. Dowd JB, Haan MN, Blythe L, Moore K, Aiello AE. Socioeconomic gradients in immune response to latent infection. *Am J Epidemiol* 2008; **167**: 112–120.
45. Ebersole JL. Humoral immune responses in gingival crevice fluid: local and systemic implications. *Periodontol 2000* 2003; **31**: 135–166.
46. Egusa H, Soysa NS, Ellepola AN, Yatani H, Samaranyake LP. Oral candidosis in HIV-infected patients. *Curr HIV Res* 2008; **6**: 485–499.
47. El Ahmer OR, Raza MW, Ogilvie MM, Weir DM, Blackwell CC. Binding of bacteria to HEP-2 cells infected with influenza A virus. *FEMS Immunol Med Microbiol* 1999; **23**: 331–341.
48. Elkins KL, Cowley SC, Bosio CM. Innate and adaptive immunity to *Francisella*. *Ann N Y Acad Sci* 2007; **1105**: 284–324.
49. Engelmann I, Petzold DR, Kosinska A, Hepkema BG, Schulz TF, Heim A. Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens. *J Med Virol* 2008; **80**: 467–477. Erratae in: *J Med Virol* 2008; **80**: 1505, *J Med Virol* 2008; **80**: 2177.
50. Fiore AE, Iverson C, Messmer T, Erdman D, Lett SM, Talkington DF, Anderson LJ, Fields B, Carlone GM, Breiman RF, Cetron MS. Outbreak of pneumonia in a long-term care facility: antecedent human parainfluenza virus 1 infection may predispose to bacterial pneumonia. *J Am Geriatr Soc* 1998; **46**: 1112–1117.



51. Gafa V, Manches O, Pastor A, Drouet E, Ambrose-Thomas P, Grillot R, Aldebert D. Human cytomegalovirus downregulates complement receptors (CR3, CR4) and decreases phagocytosis by macrophages. *J Med Virol* 2005; **76**: 361–366.
52. Gaffen SL, Hajishengallis G. A new inflammatory cytokine on the block: Re-thinking periodontal disease and the Th1/Th2 paradigm in the context of Th17 cells and IL-17. *J Dent Res* 2008; **87**: 817–828.
53. Garimorth K, Kountchev J, Bellmann R, Semenzitz B, Weiss G, Joannidis M. Lemierre's syndrome following infectious mononucleosis. *Wien Klin Wochenschr* 2008; **120**: 181–183.
54. Gemmell E, Carter CL, Grieco DA, Sugeran PB, Seymour GJ. *P. gingivalis*-specific T-cell lines produce Th1 and Th2 cytokines. *J Dent Res* 2002; **81**: 303–307.
55. Gemmell E, Seymour GJ. Immunoregulatory control of Th1/Th2 cytokine profiles in periodontal disease. *Periodontol 2000* 2004; **35**: 21–41.
56. Gemmell E, Yamazaki K, Seymour GJ. The role of T cells in periodontal disease: homeostasis and autoimmunity. *Periodontol 2000* 2007; **43**: 14–40.
57. Gershwin LJ, Berghaus LJ, Arnold K, Anderson ML, Corbeil LB. Immune mechanisms of pathogenetic synergy in concurrent bovine pulmonary infection with *Haemophilus somnus* and bovine respiratory syncytial virus. *Vet Immunol Immunopathol* 2005; **107**: 119–130.
58. Giacaman RA, Nobbs AH, Ross KF, Herzberg MC. *Porphyromonas gingivalis* selectively up-regulates the HIV-1 coreceptor CCR5 in oral keratinocytes. *J Immunol* 2007; **179**: 2542–2550.
59. Ginder DR. Increased susceptibility of mice infected with mouse adenovirus to *Escherichia coli*-induced pyelonephritis. *J Exp Med* 1964; **120**: 1117–1128.
60. Gozlan J, Salord JM, Chouaïd C, Duvivier C, Picard O, Meyohas MC, Petit JC. Human cytomegalovirus (HCMV) late-mRNA detection in peripheral blood of AIDS patients: diagnostic value for HCMV disease compared with those of viral culture and HCMV DNA detection. *J Clin Microbiol* 1993; **31**: 1943–1945.
61. Grande SR, Imbronito AV, Okuda OS, Lotufo RF, Magalhães MH, Nunes FD. Herpes viruses in periodontal compromised sites: comparison between HIV-positive and -negative patients. *J Clin Periodontol* 2008; **35**: 838–845.
62. Graves DT, Cochran D. The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. *J Periodontol* 2003; **74**: 391–401.
63. Gredmark S, Tilburgs T, Söderberg-Nauclér C. Human cytomegalovirus inhibits cytokine-induced macrophage differentiation. *J Virol* 2004; **78**: 10378–10389.
64. Griffin E, Krantz E, Selke S, Huang ML, Wald A. Oral mucosal reactivation rates of herpesviruses among HIV-1 seropositive persons. *J Med Virol* 2008; **80**: 1153–1159.
65. Guidotti LG, Chisari FV. Cytokine-mediated control of viral infections. *Virol* 2000; **273**: 221–227.
66. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. *Annu Rev Immunol* 2001; **19**: 65–91.
67. Gunson RN, Maclean AR, Shepherd SJ, Carman W. Simultaneous detection and quantitation of cytomegalovirus, Epstein-Barr virus, and adenovirus by use of real-time PCR and pooled standards. *J Clin Microbiol* 2009; **47**: 765–770.
68. Hai R, Chu A, Li H, Umamoto S, Rider P, Liu F. Infection of human cytomegalovirus in cultured human gingival tissue. *Virol J* 2006; **3**: 84.
69. Hament JM, Kimpen JL, Fleer A, Wolfs TF. Respiratory viral infection predisposing for bacterial disease: a concise review. *FEMS Immunol Med Microbiol* 1999; **26**: 189–195.
70. Hamilton JR, Overall JC, Glasgow LA. Synergistic effect on mortality in mice with murine cytomegalovirus and *Pseudomonas aeruginosa*, *Staphylococcus aureus*, or *Candida albicans* infections. *Infect Immun* 1976; **14**: 982–989.
71. Han X, Kawai T, Taubman MA. Interference with immune-cell-mediated bone resorption in periodontal disease. *Periodontol 2000* 2007; **45**: 76–94.
72. Hashemi FB, Ghassemi M, Faro S, Aroutcheva A, Spear GT. Induction of human immunodeficiency virus type 1 expression by anaerobes associated with bacterial vaginosis. *J Infect Dis* 2000; **181**: 1574–1580.
73. Hedner E, Vahlne A, Hirsch JM. Primary herpes simplex virus (type 1) infection delays healing of oral excisional and extraction wounds in the rat. *J Oral Pathol Med* 1990; **19**: 471–476.
74. Hedner E, Vahlne A, Kahnberg KE, Hirsch JM. Reactivated herpes simplex virus infection as a possible cause of dry socket after tooth extraction. *J Oral Maxillofac Surg* 1993; **51**: 370–376. discussion 377–378.
75. Heikkinen T, Chonmaitree T. Viral-bacterial synergy in otitis media: Implications for management. *Curr Infect Dis Reports* 2000; **2**: 154–159.
76. Hirschfeld M, Weis JJ, Toshchakov V, Salkowski CA, Cody MJ, Ward DC, Qureshi N, Michalek SM, Vogel SN. Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. *Infect Immun* 2001; **69**: 1477–1482.
77. Hochman N, Zakay-Rones Z, Shohat H, Ever-Hadani P, Ehrlich J, Schlesinger M, Morag A. Antibodies to cytomegalo and Epstein-Barr viruses in human saliva and gingival fluid. *New Microbiol* 1998; **21**: 131–139.
78. Holt SC, Ebersole JL. *Porphyromonas gingivalis*, *Treponema denticola*, and *Tannerella forsythia*: the 'red complex', a prototype polybacterial pathogenic consortium in periodontitis. *Periodontol 2000* 2005; **38**: 72–122.
79. Hourì-Haddad Y, Wilensky A, Shapira L. T-cell phenotype as a risk factor for periodontal disease. *Periodontol 2000* 2007; **45**: 67–75.
80. Huang CB, Emerson KA, Gonzalez OA, Ebersole JL. Oral bacteria induce a differential activation of HIV-1 promoter in T cells, macrophages, and dendritic cells. *Oral Microbiol Immunol* 2009 (in press).
81. Idesawa M, Sugano N, Ikeda K, Oshikawa M, Takane M, Seki K, Ito K. Detection of Epstein-Barr virus in saliva by real-time PCR. *Oral Microbiol Immunol* 2004; **19**: 230–232.
82. Ikegaya H, Motani H, Sakurada K, Sato K, Akutsu T, Yoshino M. Forensic application of Epstein-Barr virus genotype: correlation between viral genotype and geographical area. *J Virol Methods* 2008; **147**: 78–85.
83. Imamura T, Travis J, Potempa J. The biphasic virulence activities of gingipains: activation and inactivation of host proteins. *Curr Protein Pept Sci* 2003; **4**: 443–450.
84. Imbronito AV, Grande SR, Freitas NM, Okuda O, Lotufo RF, Nunes FD. Detection of Epstein-Barr virus and human

- cytomegalovirus in blood and oral samples: comparison of three sampling methods. *J Oral Sci* 2008; **50**: 25–31.
85. Imbronito AV, Okuda OS, Maria de Freitas N, Moreira Lotufo RF, Nunes FD. Detection of herpesviruses and periodontal pathogens in subgingival plaque of patients with chronic periodontitis, generalized aggressive periodontitis, or gingivitis. *J Periodontol* 2008; **79**: 2313–2321.
  86. Ishii K, Fukui M. Optimization of annealing temperature to reduce bias caused by a primer mismatch in multi-template PCR. *Appl Environ Microbiol* 2001; **67**: 3753–3755.
  87. Juvén T, Mertsola J, Waris M, Leinonen M, Ruuskanen O. Clinical response to antibiotic therapy for community-acquired pneumonia. *Eur J Pediatr* 2004; **163**: 140–144.
  88. Kajita K, Honda T, Amanuma R, Domon H, Okui T, Ito H, Yoshie H, Tabeta K, Nakajima T, Yamazaki K. Quantitative messenger RNA expression of Toll-like receptors and interferon-alpha1 in gingivitis and periodontitis. *Oral Microbiol Immunol* 2007; **22**: 398–402.
  89. Kamma JJ, Contreras A, Slots J. Herpes viruses and periodontopathic bacteria in early-onset periodontitis. *J Clin Periodontol* 2001; **28**: 879–885.
  90. Kamma JJ, Slots J. Herpesviral-bacterial interactions in aggressive periodontitis. *J Clin Periodontol* 2003; **30**: 420–426.
  91. Katzoli P, Sakellaris G, Ergazaki M, Charissis G, Spandidos DA, Sourvinos G. Detection of herpes viruses in children with acute appendicitis. *J Clin Virol* 2009; **44**: 282–286.
  92. Kawashima N, Stashenko P. Expression of bone-resorptive and regulatory cytokines in murine periapical inflammation. *Arch Oral Biol* 1999; **44**: 55–66.
  93. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. *Altern Med Rev* 2003; **8**: 223–246.
  94. Kinane DF, Demuth DR, Gorr SU, Hajishengallis GN, Martin MH. Human variability in innate immunity. *Periodontol 2000* 2007; **45**: 14–34.
  95. Klemenc P, Skaleric U, Artnik B, Nogrsek P, Marin J. Prevalence of some herpesviruses in gingival crevicular fluid. *J Clin Virol* 2005; **34**: 147–152.
  96. Konstantinidis A, Sakellari D, Papa A, Antoniadis A. Real-time polymerase chain reaction quantification of Epstein-Barr virus in chronic periodontitis patients. *J Periodontol Res* 2005; **40**: 294–298.
  97. Kosai K, Seki M, Yanagihara K, Nakamura S, Kurihara S, Imamura Y, Izumikawa K, Takeya H, Yamamoto Y, Tashiro T, Kohno S. Two-dimensional gel electrophoresis analysis in simultaneous influenza pneumonia and bacterial infection in mice. *Clin Exp Immunol* 2008; **152**: 364–371.
  98. Kubar A, Saygun I, Özdemir A, Yapar M, Slots J. Real-time polymerase chain reaction quantification of human cytomegalovirus and Epstein-Barr virus in periodontal pockets and the adjacent gingiva of periodontitis lesions. *J Periodontol Res* 2005; **40**: 97–104.
  99. Kubar A, Saygun I, Yapar M, Özdemir A, Slots J. Real-time PCR quantification of cytomegalovirus in aggressive periodontitis lesions using TaqMan technology. *J Periodontol Res* 2004; **39**: 81–86.
  100. Kuritzkes DR, Walker BD. HIV-1 pathogenesis, clinical manifestations, and treatment. In: Knipe DM, Howley PM, editors. *Fields Virology*, 5th edn. Philadelphia: Lippincott, Williams & Wilkins, 2007: 2187–2214.
  101. Lamont RJ, Yilmaz O. In or out: the invasiveness of oral bacteria. *Periodontol 2000* 2002; **30**: 61–69.
  102. Landry ML, Eid T, Bannykh S, Major E. False negative PCR despite high levels of JC virus DNA in spinal fluid: Implications for diagnostic testing. *J Clin Virol* 2008; **43**: 247–249.
  103. Lee SC, Fung CP, Lin CC, Tsai CJ, Chen KS. *Porphyromonas gingivalis* bacteremia and subhepatic abscess after renal transplantation: a case report. *J Microbiol Immunol Infect* 1999; **32**: 213–216.
  104. LeVine AM, Koeningsknecht V, Stark JM. Decreased pulmonary clearance of *S. pneumoniae* following influenza A infection in mice. *J Virol Methods* 2001; **94**: 173–186.
  105. Li H, Chen V, Chen Y, Baumgartner JC, Machida CA. Herpesviruses in endodontic pathoses: association of Epstein-Barr virus with irreversible pulpitis and apical periodontitis. *J Endod* 2009; **35**: 23–29.
  106. Li L, Michel R, Cohen J, Decarlo A, Kozarov E. Intracellular survival and vascular cell-to-cell transmission of *Porphyromonas gingivalis*. *BMC Microbiol* 2008; **8**: 26.
  107. Li Y, Zhang JC, Zhang YH. The association between infection of Epstein-Barr virus and chronic periodontitis. *Zhonghua Kou Qiang Yi Xue Za Zhi* 2004; **39**: 146–148. (Chinese).
  108. Lin YL, Chang PC, Wang Y, Li M. Identification of novel viral interleukin-10 isoforms of human cytomegalovirus AD169. *Virus Res* 2008; **131**: 213–223.
  109. Lin YL, Li M. Human cytomegalovirus and Epstein-Barr virus inhibit oral bacteria-induced macrophage activation and phagocytosis. *Oral Microbiol Immunol* 2009; **24**: 243–248.
  110. Ling LJ, Ho CC, Wu CY, Chen YT, Hung SL. Association between human herpesviruses and the severity of periodontitis. *J Periodontol* 2004; **75**: 1479–1485.
  111. Loenen WA, Bruggeman CA, Wiertz EJ. Immune evasion by human cytomegalovirus: lessons in immunology and cell biology. *Semin Immunol* 2001; **13**: 41–49.
  112. Lommer MJ, Verstraete FJ. Concurrent oral shedding of feline calicivirus and feline herpesvirus 1 in cats with chronic gingivostomatitis. *Oral Microbiol Immunol* 2003; **18**: 131–134.
  113. Lossli CG. Influenza and the interaction of viruses and bacteria in respiratory infections. *Medicine (Baltimore)* 1973; **52**: 369–384.
  114. Lucht E, Albert J, Linde A, Xu W, Brytting M, Lundeberg J, Uhlén M, Bratt G, Sandström E, Heimdahl A, Nord CE, Wahren B. Human immunodeficiency virus type 1 and cytomegalovirus in saliva. *J Med Virol* 1993; **39**: 156–162.
  115. Lucht E, Brytting M, Bjerregaard L, Julander I, Linde A. Shedding of cytomegalovirus and herpesviruses 6, 7, and 8 in saliva of human immunodeficiency virus type 1-infected patients and healthy controls. *Clin Infect Dis* 1998; **27**: 137–141.
  116. Mahanonda R, Pichyangkul S. Toll-like receptors and their role in periodontal health and disease. *Periodontol 2000* 2007; **43**: 41–55.
  117. Marchall JA. Mixed infections of intestinal viruses and bacteria in humans. In: Brogden KA, Guthmiller JM

- editors. *Polymicrobial diseases*. Washington, DC: American Society for Microbiology, 2002: 299–316.
118. Mardirossian A, Contreras A, Navazesh M, Nowzari H, Slots J. Herpesviruses 6, 7 and 8 in HIV- and non-HIV-associated periodontitis. *J Periodontol Res* 2000; **35**: 278–284.
  119. Mark KE, Wald A, Magaret AS, Selke S, Olin L, Huang ML, Corey L. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. *J Infect Dis* 2008; **198**: 1141–1149.
  120. Mbopi-Kéou FX, Bélec L, Teo CG, Scully C, Porter SR. Synergism between HIV and other viruses in the mouth. *Lancet Infect Dis* 2002; **2**: 416–424.
  121. McChlery S, Ramage G, Bagg J. Respiratory tract infections and pneumonia. *Periodontol 2000* 2009; **49**: 151–165.
  122. McCullers JA, Karlström A, Iverson AR, Loeffler JM, Fischetti VA. Novel strategy to prevent otitis media caused by colonizing *Streptococcus pneumoniae*. *PLoS Pathog* 2007; **3**: e28.
  123. McCullers JA, Rehg JE. Lethal synergism between influenza virus and *Streptococcus pneumoniae*: characterization of a mouse model and the role of platelet-activating factor receptor. *J Infect Dis* 2002; **186**: 341–350.
  124. Meyer-König U, Serr A, von Laer D, Kirste G, Wolff C, Haller O, Neumann-Haefelin D, Hufert FT. Human cytomegalovirus immediate early and late transcripts in peripheral blood leukocytes: diagnostic value in renal transplant recipients. *J Infect Dis* 1995; **171**: 705–709.
  125. Michalowicz BS, Ronderos M, Camara-Silva R, Contreras A, Slots J. Human herpesviruses and *Porphyromonas gingivalis* are associated with juvenile periodontitis. *J Periodontol* 2000; **71**: 981–988.
  126. Miller CS, Avdiushko SA, Kryscio RJ, Danaher RJ, Jacob RJ. Effect of prophylactic valacyclovir on the presence of human herpesvirus DNA in saliva of healthy individuals after dental treatment. *J Clin Microbiol* 2005; **43**: 2173–2180.
  127. Miller CS, Berger JR, Mootoor Y, Avdiushko SA, Zhu H, Kryscio RJ. High prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy. *J Clin Microbiol* 2006; **44**: 2409–2415.
  128. Minoura-Etoh J, Gotoh K, Sato R, Ogata M, Kaku N, Fujioka T, Nishizono A. *Helicobacter pylori*-associated oxidant monochloramine induces reactivation of Epstein–Barr virus (EBV) in gastric epithelial cells latently infected with EBV. *J Med Microbiol* 2006; **55**: 905–911.
  129. Mizgerd JP. Acute lower respiratory tract infection. *N Engl J Med* 2008; **358**: 716–727.
  130. Mocarski ES Jr. Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system. *Cell Microbiol* 2004; **6**: 707–717.
  131. Mocarski ES Jr, Shenk T, Pass RF. Cytomegaloviruses. In: Knipe DM, Howley PM editors. *Fields Virology*, 5th edn. Philadelphia: Lippincott, Williams & Wilkins, 2007: 2702–2772.
  132. Mogensen TH, Paludan SR. Molecular pathways in virus-induced cytokine production. *Microbiol Mol Biol Rev* 2001; **65**: 131–150.
  133. Moghim SH, Chalabi M, Abed AM, Rezaei F, Tamizifar H. Prevalence of Epstein–Barr virus type 1 in patients with chronic periodontitis by nested-PCR. *Pak J Biol Sci* 2007; **15**: 4547–4550.
  134. Müller R, Ditzel A, Hille K, Stichling M, Ehrlich R, Illmer T, Ehninger G, Rohayem J. Detection of herpesvirus and adenovirus co-infections with diagnostic DNA-microarrays. *J Virol Methods* 2009; **155**: 161–166.
  135. Nachtwey J, Spencer JV. HCMV IL-10 suppresses cytokine expression in monocytes through inhibition of Nuclear Factor-kappaB. *Viral Immunol* 2008; **21**: 477–482.
  136. Nagasawa T, Kiji M, Yashiro R, Hormdee D, Lu H, Kunze M, Suda T, Koshy G, Kobayashi H, Oda S, Nitta H, Ishikawa I. Roles of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in periodontal health and disease. *Periodontol 2000* 2007; **43**: 65–84.
  137. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)–seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. *J Infect Dis* 2002; **185**: 273–282.
  138. Nishiyama SA, Nakano V, Velásquez-Melendez G, Avila-Campos MJ. Occurrence of herpes simplex virus 1 and three periodontal bacteria in patients with chronic periodontitis and necrotic pulp. *Can J Microbiol* 2008; **54**: 326–330.
  139. Nowzari H, Botero JE, DeGiacomo M, Villacres MC, Rich SK. Microbiology and cytokine levels around healthy dental implants and teeth. *Clin Implant Dent Relat Res* 2008; **10**: 166–173.
  140. Nowzari H, Jorgensen MG, Ta TT, Contreras A, Slots J. Aggressive periodontitis associated with Fanconi’s anemia. A case report. *J Periodontol* 2001; **72**: 1601–1606.
  141. Olczak-Kowalczyk D, Pawłowska J, Cukrowska B, Kluge P, Witkowska-Vogt E, Dzierzanowska-Fangrat K, Wrześniewska D, Smirska E, Grenda R. Local presence of cytomegalovirus and *Candida* species vs oral lesions in liver and kidney transplant recipients. *Ann Transplant* 2008; **13**: 28–33.
  142. Ongrádi J, Sallay K, Kulcsár G. The decreased antibacterial activity of oral polymorphonuclear leukocytes coincides with the occurrence of virus-carrying oral lymphocytes and epithelial cells. *Folia Microbiol (Praha)* 1987; **32**: 438–447.
  143. Pacheco JJ, Coelho C, Salazar F, Contreras A, Slots J, Velazco CH. Treatment of Papillon-Lefèvre syndrome periodontitis. *J Clin Periodontol* 2002; **29**: 370–374.
  144. Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK. American Society of Transplantation Infectious Diseases Community of Practice; Canadian Society of Transplantation. Interlaboratory comparison of cytomegalovirus viral load assays. *Am J Transplant* 2009; **9**: 258–268.
  145. Pang X, Humar A, Preiksaitis JK. Concurrent genotyping and quantitation of cytomegalovirus gB genotypes in solid-organ-transplant recipients by use of a real-time PCR assay. *J Clin Microbiol* 2008; **46**: 4004–4010.
  146. Parra B, Slots J. Detection of human viruses in periodontal pockets using polymerase chain reaction. *Oral Microbiol Immunol* 1996; **11**: 289–293.
  147. Pass RF. Epidemiology and transmission of cytomegalovirus infection. *J Infect Dis* 1985; **152**: 243–248.
  148. Paster BJ, Olsen I, Aas JA, Dewhirst FE. The breadth of bacterial diversity in the human periodontal pocket and other oral sites. *Periodontol 2000* 2006; **42**: 80–87.



149. Patel R. Valaciclovir: development, clinical utility and potential. *Expert Opin Investig Drugs* 1997; **6**: 173–189.
150. Peleg AY, Husain S, Qureshi ZA, Silveira FP, Sarumi M, Shutt KA, Kwak EJ, Paterson DL. Risk factors, clinical characteristics, and outcome of *Nocardia* infection in organ transplant recipients: a matched case-control study. *Clin Infect Dis* 2007; **44**: 1307–1314.
151. Pellett PE, Roizman B. The family *Herpesviridae*: A brief introduction. In: Knipe DM, Howley PM editors. *Fields Virology*, 5th edn. Philadelphia: Lippincott, Williams & Wilkins, 2007: 2479–2499.
152. Pereira CM, Gasparetto PF, Corrêa ME, Costa FF, de Almeida OP, Barjas-Castro ML. Human herpesvirus 6 in oral fluids from healthy individuals. *Arch Oral Biol* 2004; **49**: 1043–1046.
153. Potempa J, Banbula A, Travis J. Role of bacterial proteinases in matrix destruction and modulation of host responses. *Periodontol 2000* 2000; **24**: 153–192.
154. Powers C, DeFilippis V, Malouli D, Früh K. Cytomegalovirus immune evasion. *Curr Top Microbiol Immunol* 2008; **325**: 333–359.
155. Prato GP, Rotundo R, Magnani C, Ficarra G. Viral etiology of gingival recession. A case report. *J Periodontol* 2002; **73**: 110–114.
156. Preshaw PM. Definitions of periodontal disease in research. *J Clin Periodontol* 2009; **36**: 1–2.
157. Puchhammer-Stöckl E, Görzer I. Cytomegalovirus and Epstein–Barr virus subtypes – the search for clinical significance. *J Clin Virol* 2006; **36**: 239–248.
158. Rams TE, Listgarten MA, Slots J. Utility of radiographic crestal lamina dura for predicting periodontitis disease-activity. *J Clin Periodontol* 1994; **21**: 571–576.
159. Rams TE, Listgarten MA, Slots J. *Actinobacillus actinomycescomitans* and *Porphyromonas gingivalis* subgingival presence, species-specific serum immunoglobulin G antibody levels, and periodontitis disease recurrence. *J Periodontal Res* 2006; **41**: 228–234.
160. Raué HP, Brien JD, Hammarlund E, Slifka MK. Activation of virus-specific CD8+ T cells by lipopolysaccharide-induced IL-12 and IL-18. *J Immunol* 2004; **173**: 6873–6881.
161. Reddehase MJ, Simon CO, Seckert CK, Lemmermann N, Grzimek NK. Murine model of cytomegalovirus latency and reactivation. *Curr Top Microbiol Immunol* 2008; **325**: 315–331.
162. Reddy MS. Reaching a better understanding of non-oral disease and the implication of periodontal infections. *Periodontol 2000* 2007; **44**: 9–14.
163. Rentenaar RJ, Gamadia LE, van DerHoek N, van Diepen FN, Boom R, Weel JF, Wertheim-van Dillen PM, van Lier RA, ten Berge IJ. Development of virus-specific CD4(+) T cells during primary cytomegalovirus infection. *J Clin Invest* 2000; **105**: 541–548.
164. Rickinson AB, Kieff E. Epstein–Barr virus. In: Knipe DM, Howley PM editors. *Fields Virology*, 5th edn. Philadelphia: Lippincott, Williams & Wilkins, 2007: 2656–2700.
165. Roivainen M, Viik-Kajander M, Palosuo T, Toivanen P, Leinonen M, Saikku P, Tenkanen L, Manninen V, Hovi T, Mänttari M. Infections, inflammation, and the risk of coronary heart disease. *Circulation* 2000; **101**: 252–257.
166. Roland PS, Parry DA, Stroman DW. Microbiology of acute otitis media with tympanostomy tubes. *Otolaryngol Head Neck Surg* 2005; **133**: 585–595.
167. Root-Bernstein R, Vonck J, Podufaly A. Antigenic complementarity between coxsackie virus and streptococcus in the induction of rheumatic heart disease and autoimmune myocarditis. *Autoimmunity* 2009; **42**: 1–16.
168. Rotola A, Cassai E, Farina R, Caselli E, Gentili V, Lazzarotto T, Trombelli L. Human herpesvirus 7, Epstein–Barr virus and human cytomegalovirus in periodontal tissues of periodontally diseased and healthy subjects. *J Clin Periodontol* 2008; **35**: 831–837.
169. Rudney JD, Chen R, Sedgewick GJ. *Actinobacillus actinomycescomitans*, *Porphyromonas gingivalis*, and *Tannerella forsythensis* are components of a polymicrobial intracellular flora within human buccal cells. *J Dent Res* 2005; **84**: 59–63.
170. Ruohola A, Meurman O, Nikkari S, Skottman T, Salmi A, Waris M, Osterback R, Eerola E, Allander T, Niesters H, Heikkinen T, Ruuskanen O. Microbiology of acute otitis media in children with tympanostomy tubes: prevalences of bacteria and viruses. *Clin Infect Dis* 2006; **43**: 1417–1422.
171. Sabeti M, Slots J. Herpesviral-bacterial coinfection in periapical pathosis. *J Endod* 2004; **30**: 69–72.
172. Saboia-Dantas CJ, Coutin de Toledo LF, Siqueira JF Jr, Sampaio-Filho HR, Carvalho JJ, Pereira MJ. Natural killer cells and alterations in collagen density: signs of periradicular herpesvirus infection? *Clin Oral Invest* 2008; **12**: 129–135.
173. Şahin S, Saygun I, Kubar A, Slots J. Periodontitis lesions are the main source of salivary cytomegalovirus. *Oral Microbiol Immunol* 2009; **24**: 340–342.
174. Samarayanake LP, Leung WK, Jin L. Oral mucosal fungal infections. *Periodontol 2000* 2009; **49**: 39–59.
175. Sandvej K, Zhou XG, Hamilton-Dutoit S. EBNA-1 sequence variation in Danish and Chinese EBV-associated tumours: evidence for geographical polymorphism but not for tumour-specific subtype restriction. *J Pathol* 2000; **191**: 127–131.
176. Santangelo R, D’Ercole S, Graffeo R, Marchetti S, Deli G, Nacci A, Piccolomini R, Cattani P, Fadda G. Bacterial and viral DNA in periodontal disease: a study using multiplex PCR. *New Microbiol* 2004; **27**: 133–137.
177. Saygun I, Kubar A, Özdemir A, Slots J. Periodontitis lesions are a source of salivary cytomegalovirus and Epstein–Barr virus. *J Periodontal Res* 2005; **40**: 187–191.
178. Saygun I, Kubar A, Özdemir A, Yapar M, Slots J. Herpesviral-bacterial interrelationships in aggressive periodontitis. *J Periodontal Res* 2004; **39**: 207–212.
179. Saygun I, Kubar A, Şahin S, Şener K, Slots J. Quantitative analysis of association between herpesviruses and bacterial pathogens in periodontitis. *J Periodontal Res* 2008; **43**: 352–359.
180. Saygun I, Yapar M, Özdemir A, Kubar A, Slots J. Human cytomegalovirus and Epstein–Barr virus type 1 in periodontal abscesses. *Oral Microbiol Immunol* 2004; **19**: 83–87.
181. Schenkein HA, Barbour SE, Tew JG. Cytokines and inflammatory factors regulating immunoglobulin production in aggressive periodontitis. *Periodontol 2000* 2007; **45**: 113–127.
182. Schenkein HA, Van Dyke TE. Early-onset periodontitis: systemic aspects of etiology and pathogenesis. *Periodontol 2000* 1994; **6**: 7–25.

183. Schloss L, van Loon AM, Cinque P, Cleator G, Echevarria JM, Falk KI, Klapper P, Schirm J, Vestergaard BF, Niesters H, Popow-Kraupp T, Quint W, Linde A. An international external quality assessment of nucleic acid amplification of herpes simplex virus. *J Clin Virol* 2003; **28**: 175–185.
184. Seki M, Yanagihara K, Higashiyama Y, Fukuda Y, Kaneko Y, Ohno H, Miyazaki Y, Hirakata Y, Tomono K, Kadota J, Tashiro T, Kohno S. Immunokinetics in severe pneumonia due to influenza virus and bacteria coinfection in mice. *Eur Respir J* 2004; **24**: 143–149.
185. Severien C, Teig N, Riedel F, Hohendahl J, Rieger C. Severe pneumonia and chronic lung disease in a young child with adenovirus and *Bordetella pertussis* infection. *Pediatr Infect Dis J* 1995; **14**: 400–401.
186. Seymour GJ, Gemmell E, Reinhardt RA, Eastcott J, Taubman MA. Immunopathogenesis of chronic inflammatory periodontal diseases: cellular and molecular mechanisms. *J Periodontol Res* 1993; **28**: 478–486.
187. Sigusch BW, Wutzler A, Nietzsche T, Glockmann E. Evidence for a specific crevicular lymphocyte profile in aggressive periodontitis. *J Periodontol Res* 2006; **41**: 391–396.
188. Slots J. Selection of antimicrobial agents in periodontal therapy. *J Periodontol Res* 2002; **37**: 389–398.
189. Slots J. Herpesviruses in periodontal diseases. *Periodontol 2000* 2005; **38**: 33–62.
190. Slots J. Oral viral infections of adults. *Periodontol 2000* 2009; **49**: 60–86.
191. Slots J, Contreras A. Herpesviruses: a unifying causative factor in periodontitis? *Oral Microbiol Immunol* 2000; **15**: 277–280.
192. Slots J, Genco RJ. Black-pigmented *Bacteroides* species, *Capnocytophaga* species, and *Actinobacillus actinomycetemcomitans* in human periodontal disease: virulence factors in colonization, survival, and tissue destruction. *J Dent Res* 1984; **63**: 412–421.
193. Slots J, Kamma JJ, Sugar C. The herpesvirus-*Porphyromonas gingivalis*-periodontitis axis. *J Periodont Res* 2003; **38**: 318–323.
194. Slots J, Nowzari H, Sabeti M. Cytomegalovirus infection in symptomatic periapical pathosis. *Int Endod J* 2004; **37**: 519–524. Erratum in: *Int Endod J* 2005; **38**: 854.
195. Slots J, Saygun I, Sabeti M, Kubar A. Epstein-Barr virus in oral diseases. *J Periodontol Res* 2006; **41**: 235–244.
196. Slots J, Kamma JJ. Cytomegalovirus periodontal presence is associated with subgingival *Dialister pneumosintes* and alveolar bone loss. *Oral Microbiol Immunol* 2002; **17**: 369–374.
197. Slots J, Ting M. *Actinobacillus actinomycetemcomitans* and *Porphyromonas gingivalis* in human periodontal disease: occurrence and treatment. *Periodontol 2000* 1999; **20**: 82–121.
198. Smith H, Sweet C. Cooperation between viral and bacterial pathogens in causing human respiratory disease. In: Brogden KA, Guthmiller JM editors. *Polymicrobial diseases*. Washington, DC: American Society for Microbiology, 2002: 201–112.
199. Smith MacDonald E, Nowzari H, Contreras A, Flynn J, Morrison J, Slots J. Clinical and microbiological evaluation of a bioabsorbable and a nonresorbable barrier membrane in the treatment of periodontal intraosseous lesions. *J Periodontol* 1998; **69**: 445–453.
200. Söderberg-Nauclér C. HCMV microinfections in inflammatory diseases and cancer. *J Clin Virol* 2008; **41**: 218–223.
201. Stals FS, vd Bogaard AE, Bruggeman CA. Prevention of bacteraemia by systemic ciprofloxacin treatment in rat cytomegalovirus-infected immunocompromised rats. *J Antimicrob Chemother* 1994; **34**: 101–110.
202. Stathopoulou PG, Benakanakere MR, Galicia JC, Kinane DF. The host cytokine response to *Porphyromonas gingivalis* is modified by gingipains. *Oral Microbiol Immunol* 2009; **24**: 11–17.
203. Stern J, Shai E, Zaks B, Halabi A, Hourri-Haddad Y, Shapira L, Palmon A. Reduced expression of gamma interferon in serum and marked lymphoid depletion induced by *Porphyromonas gingivalis* increase murine morbidity and mortality due to cytomegalovirus infection. *Infect Immun* 2004; **72**: 5791–5798.
204. Stratton KR, Durch J, Lawrence RS. Institute of Medicine (US) Committee to Study Priorities for Vaccine Development. *Vaccines for the 21st century: a tool for decision making*. Washington, DC: National Academies Press, 2000.
205. Sugano N, Ikeda K, Oshikawa M, Idesawa M, Tanaka H, Sato S, Ito K. Relationship between *Porphyromonas gingivalis*, Epstein-Barr virus infection and reactivation in periodontitis. *J Oral Sci* 2004; **46**: 203–206.
206. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. *Nature* 2009; **457**: 557–561.
207. Sunde PT, Olsen I, Enersen M, Beiske K, Grinde B. Human cytomegalovirus and Epstein-Barr virus in apical and marginal periodontitis: A role in pathology? *J Med Virol* 2008; **80**: 1007–1011.
208. Sunde PT, Olsen I, Enersen M, Grinde B. Patient with severe periodontitis and subgingival Epstein-Barr virus treated with antiviral therapy. *J Clin Virol* 2008; **42**: 176–178.
209. Svahn A, Berggren J, Parke A, Storsaeter J, Thorstensson R, Linde A. Changes in seroprevalence to four herpesviruses over 30 years in Swedish children aged 9–12 years. *J Clin Virol* 2006; **37**: 118–123.
210. Syrjänen S, Leimola-Virtanen R, Schmidt-Westhausen A, Reichart PA. Oral ulcers in AIDS patients frequently associated with cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections. *J Oral Pathol Med* 1999; **28**: 204–209.
211. Tabanella G, Nowzari H. Cytomegalovirus-associated periodontitis and Guillain-Barré syndrome. *J Periodontol* 2005; **76**: 2306–2311.
212. Tam V, O'Brien-Simpson NM, Chen YY, Sanderson CJ, Kinnear B, Reynolds EC. The RgpA-Kgp proteinase-adhesin complexes of *Porphyromonas gingivalis* inactivate the Th2 cytokines interleukin-4 and interleukin-5. *Infect Immun* 2009; **77**: 1451–1458.
213. Tang YW, Espy MJ, Persing DH, Smith TF. Molecular evidence and clinical significance of herpesvirus coinfection in the central nervous system. *J Clin Microbiol* 1997; **35**: 2869–2872.
214. Tantivanich S, Laohapand P, Thaweeboon S, Desakorn V, Wuthinuntiwong P, Chalermtaranakul S, Pansri P, Amarapal P, Balachandra K, Chantraita W, Dhepakson P. Prevalence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus in periodontitis patients and healthy



- subjects in the Thai population. *Southeast Asian J Trop Med Public Health* 2004; **35**: 635–640.
215. Taubman MA, Haffajee AD, Socransky SS, Smith DJ, Ebersole JL. Longitudinal monitoring of human antibody in subjects with destructive periodontal diseases. *J Periodontol Res* 1992; **27**: 511–521.
216. Taubman MA, Kawai T. Involvement of T-lymphocytes in periodontal disease and in direct and indirect induction of bone resorption. *Crit Rev Oral Biol Med* 2001; **12**: 125–135.
217. Teughels W, Sliepen I, Quirynen M, Haake SK, Van Eldere J, Fives-Taylor P, Van Ranst M. Human cytomegalovirus enhances *A. actinomycetemcomitans* adherence to cells. *J Dent Res* 2007; **86**: 175–180.
218. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. *JAMA* 2004; **292**: 1333–1340.
219. Ting M, Contreras A, Slots J. Herpesviruses in localized juvenile periodontitis. *J Periodontol Res* 2000; **35**: 17–25.
220. Titball RW. Vaccines against intracellular bacterial pathogens. *Drug Discov Today* 2008; **13**: 596–600.
221. Tolo K, Helgeland K. Fc-binding components: a virulence factor in *Actinobacillus actinomycetemcomitans*? *Oral Microbiol Immunol* 1991; **6**: 373–377.
222. Tribble GD, Lamont RJ. Bacterial invasion of epithelial cells and spreading in periodontal tissue: intracellular infection. *Periodontol 2000* 2009 (this volume)
223. Udagawa N, Sato N, Yang S, Nakamura M, Yamashita T, Nakamura H, Noguchi T. Signal transduction of lipopolysaccharide-induced osteoclast differentiation. *Periodontol 2000* 2007; **43**: 56–64.
224. Vilkkuna-Rautiainen T, Pussinen PJ, Roivainen M, Petäys T, Jousilahti P, Hovi T, Vartiainen E, Asikainen S. Serum antibody response to periodontal pathogens and herpes simplex virus in relation to classic risk factors of cardiovascular disease. *Int J Epidemiol* 2006; **35**: 1486–1494.
225. Vitkov L, Krautgartner WD, Hannig M. Bacterial internalization in periodontitis. *Oral Microbiol Immunol* 2005; **20**: 317–321.
226. Wakiguchi H, Hisakawa H, Kubota H, Kurashige T. Strong response of T cells in infants with dual infection by Epstein–Barr virus and cytomegalovirus. *Pediatr Int* 1999; **41**: 484–489.
227. Wald A, Huang ML, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. *J Infect Dis* 2003; **188**: 1345–1351.
228. Walling DM, Brown AL, Etienne W, Keitel WA, Ling PD. Multiple Epstein–Barr virus infections in healthy individuals. *J Virol* 2003; **77**: 6546–6550.
229. Wara-Aswapati N, Boch JA, Auron PE. Activation of interleukin 1beta gene transcription by human cytomegalovirus: molecular mechanisms and relevance to periodontitis. *Oral Microbiol Immunol* 2003; **18**: 67–71.
230. Watanabe SA, de Fátima Correia-Silva J, Horta MC, da Costa JE, Gomez RS. EBV-1 and HCMV in aggressive periodontitis in Brazilian patients. *Braz Oral Res* 2007; **21**: 336–341.
231. White MK, Gorrill TS, Khalili K. Reciprocal transactivation between HIV-1 and other human viruses. *Virology* 2006; **352**: 1–13.
232. Winther B, Alper CM, Mandel EM, Doyle WJ, Hendley JO. Temporal relationships between colds, upper respiratory viruses detected by polymerase chain reaction, and otitis media in young children followed through a typical cold season. *Pediatrics* 2007; **119**: 1069–1075.
233. Wohlleben G, Erb KJ. Immune stimulatory strategies for the prevention and treatment of asthma. *Curr Pharm Des* 2006; **12**: 3281–3292.
234. Wu YM, Yan J, Chen LL, Sun WL, Gu ZY. Infection frequency of Epstein–Barr virus in subgingival samples from patients with different periodontal status and its correlation with clinical parameters. *J Zhejiang Univ Sci B* 2006; **7**: 876–883.
235. Wu YM, Yan J, Ojcius DM, Chen LL, Gu ZY, Pan JP. Correlation between infections with different genotypes of human cytomegalovirus and Epstein–Barr virus in subgingival samples and periodontal status of patients. *J Clin Microbiol* 2007; **45**: 3665–3670. Erratum in: *J Clin Microbiol* 2008; **46**: 836.
236. Yager EJ, Szaba FM, Kummer LW, Lanzer KG, Burkum CE, Smiley ST, Blackman MA. Gamma-herpesvirus-induced protection against bacterial infection is transient. *Viral Immunol* 2009; **22**: 67–72.
237. Yano H, Okitsu N, Hori T, Watanabe O, Kisu T, Hatagishi E, Suzuki A, Okamoto M, Ohmi A, Suetake M, Sagai S, Kobayashi T, Nishimura H. Detection of respiratory viruses in nasopharyngeal secretions and middle ear fluid from children with acute otitis media. *Acta Otolaryngol* 2008; **13**: 1–6.
238. Yano H, Okitsu N, Watanabe O, Kisu T, Hori T, Hatagishi E, Okamoto M, Ohmi A, Yamada K, Sagai S, Suetake M, Kobayashi T, Nishimura H. Acute otitis media associated with cytomegalovirus infection in infants and children. *Int J Pediatr Otorhinolaryngol* 2007; **71**: 1443–1447.
239. Yapar M, Saygun I, Özdemir A, Kubar A, Şahin S. Prevalence of human herpesviruses in patients with aggressive periodontitis. *J Periodontol* 2003; **74**: 1634–1640.
240. Yazdi KA, Sabeti M, Jabalameli F, Eman eini M, Kolahdouzan SA, Slots J. Relationship between human cytomegalovirus transcription and symptomatic apical periodontitis in Iran. *Oral Microbiol Immunol* 2008; **23**: 510–514.
241. Yildirim S, Yapar M, Kubar A. Detection and quantification of herpesviruses in Kostmann syndrome periodontitis using real-time polymerase chain reaction: a case report. *Oral Microbiol Immunol* 2006; **21**: 73–78.
242. Yin MT, Dobkin JF, Grbic JT. Epidemiology, pathogenesis, and management of human immunodeficiency virus infection in patients with periodontal disease. *Periodontol 2000* 2007; **44**: 55–81.
243. Zajacova A, Dowd JB, Aiello AE. Socioeconomic and race/ethnic patterns in persistent infection burden among U.S. adults. *J Gerontol A Biol Sci Med Sci* 2009; **64**: 272–279.